ſ

Update date: February 1, 2024

Group No. 5: Endocrinology and Metabolism

RISEDRONIC ACID/ CHOLECALCIFEROL

Description	Indications	Route of administration and dosage
TABLET	Prophylaxis and treatment of	Oral
	Postmenopausal	
Each tablet contains: Risedronate sodium	osteoporosis, with risk	Adults and people over 18 years of age:
35.00 mg	factors.	
		35 mg/ 2800 IU every week (same day) on an
Vitamin D3 (cholecalciferol) 28.00 mg	Prophylaxis and treatment	empty stomach or 30 minutes before eating.
Equivalent to 2800 IU	of corticosteroid-induced	
	osteoporosis	
Package with 10 tablets.		
	TABLET Each tablet contains: Risedronate sodium 35.00 mg Vitamin D3 (cholecalciferol) 28.00 mg	TABLET Prophylaxis and treatment of Postmenopausal osteoporosis, with risk factors. Vitamin D3 (cholecalciferol) 28.00 mg Prophylaxis and treatment of corticosteroid-induced osteoporosis

Generalities

Risedronate inhibits osteoclast-mediated bone resorption; It is a pyrivinyl bisphosphonate, which binds to bone hydroxyapatite. In this way, bone turnover is reduced, preserving the normal osteoblastic activity of the bone, as well as mineralization. Vitamin D deficiency is a risk factor for osteopenia and bone fractures. Serum values of 1.25 OHD < 15 ng/mL (37mM/L) progressively produce a decrease in bone mineralization, which can reach 80 to 90% in the most severe cases, and hypocalcemia that produces secondary hyperparathyroidism with an increase in bone resorption.

Calcium absorption is promoted by vitamin D and parathyroid hormone. Vitamin D is metabolized in the body resulting in 1, 25dihydroxycholecalciferol, this is necessary for the active transport of calcium in the intestine, the excretion of calcium is carried out by the kidney. Parathyroid hormone stimulates calcium reabsorption at the kidney level.

Risk in Pregnancy c
Adverse effects
General: pain, dyspepsia, nausea, abdominal pain, constipation, diarrhea, gastrointestinal disorders, musculoskeletal pain, headache, esophagitis, esophageal ulcer, gastritis, dysphagia, duodenitis, glossitis, esophageal stenosis. Iritis was observed as a very rare event in clinical studies.
Contraindications and Precautions
Contraindications
Hypersensitivity to the active ingredients or any of the excipients. Hypocalcemia. Pregnancy and lactation Severe renal failure (creatinine clearance < 30 mL/minute). Abnormalities in the esophagus (circumstances that delay esophageal emptying such as stricture or achalasia). Inability to stand or sit upright for at least 30 minutes. Calcium lithiasis, renal lithiasis, tissue calcification, for example, nephrocalcinosis. Prolonged immobilization accompanied by hypercalciuria and/or hypercalcemia. Precautions: foods, beverages (other than plain water) and drugs containing polyvalent cations (such as calcium, magnesium, iron, and aluminum) may interfere with the absorption of risedronic acid/ cholecalciferol should not be taken simultaneously.
Therefore, to obtain benefits from the risedronic acid/cholecalciferol combination, patients should take the tablet at least 30 minutes before the first meal or drink of the day, or at least two hours before or after eating food. or drinks at any other time of the day.

Interactions

Concomitant ingestion of medications that contain polyvalent cations (for example: calcium, magnesium, iron and aluminum) interferes with the absorption of risedronate, so, if indicated, it should be taken at another time of day.

BUROSUMAB

Clue	Description	Indications	Route of administration and dosage
010.000.7017.00	SOLUTION Each vial contains: burosumab 10 mg Container with a vial bottle with 1 mL (10 mg/mL) SOLUTION	Treatment of X-linked hypophosphatemia in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease.	Subcutaneous Pediatric patients (1 to less than 18 years of age): Recommended starting dosage regimen of 0.8 mg/kg body weight, rounded to the nearest Nearest 10 mg given every two weeks. The minimum starting dose is 10 mg up to a maximum dose of 90 mg. Dose increase: Reassess level

	Each vial contains: burosumab 20 mg			of fasting serum phosphorus every 4 weeks. If serum phosphorus is below the reference range for age, the dose may be increased in steps to approximately 2 mg/ kg. Dose reduction: If serum phosphorus is above the reference range for age, discontinue the next dose and reevaluate serum phosphorus level at 4 weeks. Once serum phosphorus is below the reference range for age, treatment can be restarted.		
010.000.7017.01 Contai	her with a vial with 1 mL (20 mg/mL) SOLUTION Each vial contains:					
	burosumab 30 mg					
010.000.7017.02 Contai	ner with a vial with 1 mL (30 mg/mL)					
recombination te	chnology using Chinese hams			Dr 23 (FGF23), produced by DNA		
Risk in Preg	Tancy	U				
L hun a ra a na iti vitu i		Adverse		tions.		
Hypersensitivity,	hyperphosphatemia, risk of ne	phrocalcinosis	, injection site read	tions.		
with burosumab if ser	Lontraindications and Precautions Hypersensitivity to the components of the formula, simultaneous administration with oral phosphate or active vitamin D analogues, do not initiate treatment with burosumab if serum phosphorus is between or above the normal range at age, severe deterioration of renal FUNCTION or end-stage renal disease because these conditions are associated with abnormal mineral metabolism.					
		Interac	ctions	7		
No drug interacti	on studies have been conducte	ed with burosu	mab.			
BROMOCRY	f	ſ	Indiantiana	1		
		Inhibitio	Indications	Route of administration and dosage		
· · · · · · · · · · · · · · · · · · ·	Description TABLET		on of lactation.	Oral.		
· · · · · · · · · · · · · · · · · · ·	Description	Hyperp		, i i i i i i i i i i i i i i i i i i i		
· · · · · · · · · · · · · · · · · · ·	Description TABLET Each tablet contains:	Hyperp associa	on of lactation. rolactinemia	Oral.		
Clue	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine.	Hyperp associa	on of lactation. rolactinemia ted with amenorrhea actorrhea.	Oral. Adults:		
· · · · · · · · · · · · · · · · · · ·	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg	Hyperp associa and gai	on of lactation. rolactinemia ted with amenorrhea actorrhea. ggaly.	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours.		
Clue	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine.	Hyperp associa and gal Acrome Parkins	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism.	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours.		
Clue 010.000.1096.00	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w	Hyperp associa and gal Acrome Parkins Genera pamine turnov	on of lactation. rolactinemia ted with amenorrhea actorrhea. ggaly. sonism. lities rer and inhibits the	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours.		
Clue 010.000.1096.00 It stimulates dop levels of other pit patients with acro	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly.	Hyperp associa and gal Acrome Parkins Genera pamine turnov ith acromegaly	on of lactation. rolactinemia ted with amenorrhea actorrhea. ggaly. sonism. lities rer and inhibits the	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days.		
Clue 010.000.1096.00 It stimulates dopa levels of other pit	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly.	Hyperp associa and gal Acrome Parkins Genera pamine turnov	on of lactation. rolactinemia ted with amenorrhea actorrhea. ggaly. sonism. lities rer and inhibits the	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days.		
Clue 010.000.1096.00 It stimulates dopa levels of other pit patients with acro Risk in Preg	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly. nancy	Hyperp associa and gal Acrome Parkins Genera pamine turnov ith acromegaly c Adverse	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism. litities rer and inhibits the r it may reduce the effects	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days. release of prolactin without affecting normal elevated levels of growth hormone in		
Clue 010.000.1096.00 It stimulates dopa levels of other pit patients with acro Risk in Preg	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly. nancy	Hyperp associa and gal Acrome Parkins Genera pamine turnov ith acromegaly c Adverse	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism. litities rer and inhibits the r it may reduce the effects	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days.		
Clue 010.000.1096.00 It stimulates dopa levels of other pit patients with acro Risk in Preg	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly. hancy , vomiting, low blood pressure, h	Hyperp associa and ga Acrome Parkins Genera pamine turnov ith acromegaly c Adverse eadache, halluc	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism. litities rer and inhibits the r it may reduce the effects	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days. release of prolactin without affecting normal elevated levels of growth hormone in		
Clue 010.000.1096.00 It stimulates dop levels of other pit patients with acro Risk in Preg Nausea, dizziness Contraindications	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly. hancy , vomiting, low blood pressure, h	Hyperp associa and ga Acrome Parkins Genera pamine turnov ith acromegaly c Adverse eadache, halluc	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism. lities rer and inhibits the r it may reduce the effects inations, depression and Precautions	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days. release of prolactin without affecting normal elevated levels of growth hormone in		
Clue 010.000.1096.00 It stimulates dop levels of other pit patients with acro Risk in Preg Nausea, dizziness Contraindications	Description TABLET Each tablet contains: Bromocriptine mesylate equivalent to 2.5 mg of bromocriptine. Package with 14 tablets. amine receptors, decreases do uitary hormones. In patients w omegaly. hancy , vomiting, low blood pressure, h Coi S: Hypersensitivity to ergot deriv	Hyperp associa and ga Acrome Parkins Genera pamine turnov ith acromegaly c Adverse eadache, halluc	on of lactation. rolactinemia ted with amenorrhea actorrhea. agaly. sonism. litities rer and inhibits the r it may reduce the effects inations, depression and Precautions ampsia and Rayna	Oral. Adults: 1.25 to 2.5 mg/day. Fraction for every 8 hours. Inhibition of lactation: 5 mg every 12 hours, for 14 days. release of prolactin without affecting normal elevated levels of growth hormone in		

Antidopaminergic medications decrease the effectiveness of bromocriptine. Antiparkinsonian drugs increase their pharmacological effect.

Clue	Description	n Indications	Route of administration and dosage
010.000.1042.00	TABLET Each tablet contains: Glibenclamide 5 mg. Package with 50 tablets.	Diabetes mellitus type 2.	Oral. Adults: 2.5 to 5 mg every 24 hours, after food. Maximum dose 20 mg/day. Doses greater than 10 mg should be administered every 12 hours.
	elease of insulin.	Generalities Ifonylureas that stimulates the activity of c	⊥ the beta cells of the pancreas,
Hypoglycemia, urtic	aria, fatigue, weakness, heada	Adverse effects che, nausea, diarrhea, reactive hepatitis, hemolytic Contraindications and Precautions	anemia and spinal hypoplasia.
	ns: Hypersensitivity to the	che, nausea, diarrhea, reactive hepatitis, hemolytic	

TABLETS Diabetes mellitus type 2 Oral Each tablet contains: Giimepiride 2 mg Adults 010.000.6337.01 Container with 30 tablets The initial dose is 1 mg once a day, if necessary, the increased, it is recommended that the increase doe beased on monitoring blood glucose levels and that the dose be increased grad	
010.000.6337.01 Container with 30 tablets The dosage is established according to the results of blood and urine glucose determinations. The initial dose is 1 mg once a day, if necessary, the dose can be increased, it is recommended that the increase be based on monitoring blood	
dose can be increased, it is recommended that the increase be based on monitoring blood	
for example at intervals. for one to two weeks and according to the following guidelines: 1 mg-2 mg-3 mg-4 mg-6 mg-8 mg glimepiride once a day. Dose interval in patients with well-controlled diabetes: The usual daily dose in patients with well-controlled diabetes is 1 to 4 mg of glimepiride. Doses of more than 6 mg daily are only effective in a minimal number of patients.	
Generalities	
It inhibits protein synthesis by binding to the 50 S ribosomal subunit.	
Risk in Pregnancy c	
Adverse effects	

Local irritation. Hypersensitivity. Superinfections with prolonged use.

Contraindications and Precautions Contraindications: Hypersensitivity to drugs, do not use in fungal or fungal eye conditions. Newly born. Precautions: Do not use for more than 7 days.

Interactions

None of clinical importance.

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SUSPENSION NPH INTERMEDIATE ACTION	Diabetes mellitus type 1.	Subcutaneous or intramuscular.
	Each mL contains:	Acidosis and diabetic coma.	Adults and children:
	Isophane human insulin (DNA origin recombinant) 100 IU.	Uncontrolled type 2 diabetes mellitus.	The doses must be adjusted in each case and at the discretion of the specialist doctor.
	Human isophane zinc insulin (origin recombinant DNA) 100 IU.	Hyperkalemia.	
10.000.1050.00	Container with a 5 mL vial.		
10.000.1050.01	Container with a 10 mL vial.		
	REGULAR FAST ACTING INJECTABLE SOLUTION		Subcutaneous, intramuscular or intravenous
	Each mL contains:		Adults and children:
	Human insulin (DNA origin recombinant) 100 IU.		The doses must be adjusted in each case and at the discretion of the specialist doctor.
	Human isophane zinc insulin (origin recombinant DNA) 100 IU.		
010.000.1051.00	Container with a 5 mL vial.		
010.000.1051.01	Container with a 10 mL vial.		
	INJECTABLE SUSPENSION SLOW INTERMEDIATE ACTION	-	Subcutaneous or intramuscular.
			Adults:
	Each mL contains:		The descent he edited in the
	Human compound zinc insulin (recombinant DNA origin) 100 IU.		The doses must be adjusted in each case and at the discretion of the specialist doctor.
010.000.4157.00	Container with a 10 mL vial.		

Hormone that increases glucose transport across the membrane and influences the activity of various enzymes of intermediate metabolism.

Risk in Pregnancy	b
	Adverse effects
Immediate hypersensitivity. Hypoglycemic	c syndrome. Lipodystrophy.
	Contraindications and Precautions
Contraindications: Hypersensitivity to the	drug.

Interactions

Alcohol, beta blockers, salicylates, monoamine oxidase inhibitors and tetracyclines increase the hypoglycemic effect. Corticosteroids, thiazide diuretics and furosemide reduce the hypoglycemic effect.

METFORMIN	
Clue I	

Indications

	TABLET	Diabetes mellitus type 2.	Oral.		
	Each tablet contains:		Adults:		
	Metformin hydrochloride 850 mg.				
010.000.5165.00	Package with 30 tablets.		850 mg every 12 hours with food. Maximum dose 2550 mg per day.		
	Each tablet contains:		······································		
	Metformin hydrochloride extended release 500 mg.		Extended release 500 or 750 mg each 24 hours. The dose should not be exceeded		
			2000 mg per day.		
010.000.6275.00	Package with 30 tablets.				
Generalities Biguanide that increases the peripheral effect of insulin and decreases gluconeogenesis. Risk in Pregnancy d Adverse effects					
Gastrointestinal intolerance, headache, transient skin allergies, metallic taste and lactic acidosis.					
Contraindications and Precautions Contraindications Contraindications: Hypersensitivity to the drug, type 1 diabetes mellitus. diabetic ketoacidosis, kidney failure, liver failure, heart or lung failure, severe malnutrition, chronic alcoholism and acute alcohol poisoning. Pregnancy and lactation.					

Decreases the absorption of vitamin B12 and folic acid. Sulfonylureas promote the hypoglycemic effect. Cimetidine increases the plasma concentration of metformin.

PREDNISONE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Addison's disease.	Oral.
	Each tablet contains:	Immunoallergic or	Adults:
	Prednisone 5 mg.	inflammatory diseases.	
010.000.0472.00	Package with 20 tablets.	Nephrotic syndrome.	From 5 to 60 mg/day, single or divided dose every 8 hours. The maintenance dose is established according to the therapeutic response; and subsequently it is
	TABLET		gradually decreased until the minimum effective dose is
	Each tablet contains: Prednisone 50 mg.		reached.
	r rednisone so mg.		Maximum dose: 250 mg/day.
010.000.0473.00	Package with 20 tablets.		Children:
			0.5 to 2 mg/kg body weight/day or 25 to 60 mg/m2 of body surface, divided every 6 to 12 hours.
		Generalities	

Intermediate-acting glucocorticoid that induces RNA transcription, promoting the synthesis of enzymes responsible for its effects.

Risk in Pregnancy

b

Adverse effects

Posterior subcapsular cataract, adrenal hypoplasia, Cushing's syndrome, obesity, osteoporosis, gastritis, superinfections, glaucoma, hyperosmolar coma, hyperglycemia, muscle hypercatabolism, delayed healing and growth retardation.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and systemic mycosis.

Precautions: Peptic ulcer, systemic arterial hypertension, diabetes mellitus, liver and kidney failure and immunosuppression.

Interactions

With digitalis the risk of cardiac arrhythmias and digitalis poisoning increases. Increases the biotransformation of isoniazid. Hypokalemia increases with thiazide diuretics, furosemide and amphotericin B. Rifampicin, phenytoin and phenobarbital increase its hepatic biotransformation. With estrogen its biotransformation decreases. With antacids, its intestinal absorption decreases. Paracetamol increases the hepatotoxic metabolite.

ACARBOSE					
Clue	Description	Indications	Route of administration and dosage		
	TABLET	Diabetes mellitus type 2.	Oral.		
	Each tablet contains:		Adults:		
	Acarbose 50 mg.		50 to 100 mg every 8 hours, at the beginning of the		
010.000.5166.00	Package with 30 tablets.		three main meals.		
			Maximum dose 600 mg per day.		
21		Conorolition			
Generalities Oligosaccharide of microbial origin that reduces postprandial glycemia, by reversible and competitive inhibition of pancreatic alpha amylase and alpha- glucosidohydrolase, at the level of the intestinal villi, which slows the passage of carbohydrates to the plasma.					
Risk in Pregnancy b					
Adverse effects					
Flatulence, borborygmi, abdominal pain, diarrhea, allergic reactions, hypoglycemia and absorption syndrome poor intestinal.					
Contraindications and Precautions					
Contraindications: Hypersensitivity to the drug. Patients with ketoacidosis, malabsorption syndrome and ulcerative colitis.					
Precautions: During breastfeeding, severe renal failure and children under 18 years of age.					

Interactions

Intestinal adsorbents reduce the effect of acarbose. Insulin, metformin, and sulfonylureas increase the risk of hypoglycemia.

CARGLUMIC ACID

Clue	Description	Indications	Route of administration and dosage
	TABLET	Treatment of hyperammonemia due to:	Oral.
	Each tablet contains:	N-acetylglutamate deficiency	For glutamatosynthetase deficiency: N-acetyl
	Carglumic acid 200 mg	synthetase (NAGS) Acidemia	
		Isovaleric (IVA) Acidemia	Based on clinical experience, treatment can begin from the
010.000.6151.01	Package with 60 tablets.	Methylmalonic (MMA) Acidemia propionic (PA)	first day of life. Initial dose should be 100 mg/kg up to 250 mg/kg if necessar
10.000.0101.01	i donago mar oo donoto.		Initial dose should be 100 mg/kg up to 250 mg/kg il necessar
			It must subsequently be adjusted individually in order to
			maintain plasma levels of
			normal ammonia. In the long term, it may not be necessary to increase the dose based on body weight as long as adequate
			metabolic control is achieved; daily doses range from 10 mg.
			kg to 100 mg/kg.
			Carglumic acid response test.
			It is recommended to check the individual response to
			carglumic acid before starting long-term treatment. For example: In a child in a coma, start with a dose of between
			100 to 250 mg/kg/day and measure the plasma ammonia
			concentration at least before each administration; It should
			normalize a few hours after starting treatment with carglumic
			acid.
			In a patient with moderate hyperammonemia, administer a te
			dose of between 100 and

			I
			200 mg/kg/day for 3 days with constant protein administration and repeatedly determine plasma ammonia concentration (before and 1 hour after food); Adjust the dose to maintain normal plasma ammonia levels.
			For isovaleric acidemia, methylmalonic acidemia, and propionic acidemia: Treatment should begin after hyperammonemia in patients with organic acidemia. The initial daily dose should be 100 mg/kg, reaching up to 250 mg/kg if necessary. It must then be individually adjusted to maintain normal plasma ammonia levels.
			Methods of Administration: Based on pharmacokinetic data and clinical experience, it is recommended to divide the total daily dose between two and four doses to be administered before meals. Splitting the tablets in half allows the dosage to be adjusted as necessary.
			Occasionally it can be divided into quarters of tablets to adjust the dosage prescribed by the doctor.
			The tablets can be dissolved in a minimum of 5-10 mL of water and swallowed immediately.
1		Generalities	
the first enzyme Although the affin has been shown	of the urea cycle. Carglumic acid h nity of carbamylphosphate synthet	glutamate, which is the natu has been shown to activate h ase for carglumic acid is low	ral activator of carbamylphosphate synthetase epatic carbamylphosphate synthetase. er than for N-acetyl glutamate, carglumic acid more effective than N-acetyl glutamate as a
Risk in Preg	nancy d		
		Adverse effects	
Increased sweat	ing, increased aminotransferases,	bradycardia, diarrhea, vomit	ing, pyrexia.
Contraindication	s: Hypersensitivity to the drug.	indications and Precautions	
		Interactions	
No specific intera	action studies have been performe	d	
AGALSIDASI	Ε ΔΙ ΡΗΔ		
	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Fabry disease.	Intravenous infusion.
	Each vial contains: Agalsidase alfa 3.5 mg.		Children and adolescents between 7 and 18 years of age, adults:

0.2 mg/kg body weight, every two weeks.

Generalities

Agalsidase alfa catalyzes the hydrolysis of globotriaosylceramide (Gb3 or CTH), which cleaves a terminal galactose residue from the molecule.

Risk in Pregnancy

Container with vial bottle with

3.5 mL (1 mg/mL).

010.000.5549.00

х		
	Adverse effects	

Peripheral edema, headache, dizziness, dysgeusia, neuropathic pain, tremors, hypersomnia, hypoesthesias, paresthesias, increased lacrimation, tachycardia, palpitations, hypertension, nausea, diarrhea, vomiting, abdominal pain, acne, erythema, pruritus, rash, livedo reticularis, musculoskeletal discomfort, myalgia, low back pain, pain in the extremities, peripheral swelling, arthralgia, joint swelling. Development of IgG antibodies to the protein.

Contraindications and Precautions Contraindications: Hypersensitivity to the drug and breastfeeding. Precautions: The most common symptoms related to infusion are chills, headache, nausea, pyrexia, flushing, tachycardia, urticaria,

angioneurotic edema with a sensation of oppression, stridor, swelling of the tongue, dizziness and hyperhidrosis.

Interactions

Agalsidase alfa should not be administered concomitantly with chloroquine, amiodarone, benoquine or gentamicin, since these substances may inhibit the intracellular activity of ÿ-galactosidase.

AGALSIDASE BETA

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Fabry disease enzyme deficiency	Intravenous infusion.
	Each vial with powder or lyophilisate contains:	Alpha Galactosidase A.	Children, adolescents and adults: 1 mg/kg body weight, once every two weeks.
	Agalsidase beta 35 mg.		
010.000.5546.00	Container with vial bottle with lyophilized powder.		Administer diluted in 0.9% sodium chloride intravenous solutions, packaged in glass bottles (reconstituted patient dose in 500 mL).
	INJECTABLE SOLUTION		
	Each vial with lyophilized powder contains:		The initial infusion rate should not be greater than .25 mg/min (15 mg/hour).
	Agalsidase beta 5 mg		The total infusion period should not be less than 2 hours.
010 .000.6116.00	Container with vial bottle with lyophilized powder		

Generalities

Enzyme analogue of human Acid Alpha Galactosidase, purified by means of recombinant DNA technology, using live cell cultures from Chinese hamster ovary. Agalsidase Beta acts on the underlying cause of Fabry disease due to the deficiency, lack or malfunction of the enzyme Alpha Acid Galactosidase which causes an abnormal accumulation of GL3 (globotriosylceramide) in the vascular endothelial cells.

Risk in Pregnancy

С

Adverse effects

Nausea, vomiting, headache, paresthesia, flushing, chills, pyrexia, feeling of cold, tachycardia, bradycardia, palpitations, lacrimation, tinnitus, vertigo, dyspnea, nasal congestion, throat tightness, nasopharyngitis, wheezing cough, pruritus, erythema, urticaria, facial swelling, extremity pain, myalgia, arthralgia and lower back pain.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Patients with antibodies to agalsidase beta (rhÿGAL) are more likely to experience drug infusion-associated reactions, defined as any adverse reaction that occurs on the day of administration. These patients should be treated with caution with subsequent administration of agalsidase beta. Antibody status against agalsidase beta should be monitored regularly.

Interactions

Do not administer Agalsidase beta with chloroquine, amiodarone, benoquine or gentamicin, due to the risk of inhibition of intracellular ÿ-galactosidase activity.

ALPHA ALGLUCOSIDASE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Pompe disease due to deficiency of	Intravenous infusion.
	Each vial with powder contains:	Alpha Glucosidase enzyme acidic	Children, adolescents and adults.
	Alglucosidase alfa 50 mg.		20 mg/kg body weight, once every 2 weeks.

010.000.5548.00 Container with vial with lyophilized powder.	Administer diluted in 0.9% sodium chloride intravenous solutions, packaged in glass bottles (reconstituted dose dilute obtain to concentration of 0.5 mg/mL to 4 mg/mL).			
	Initial rate of 1 mg/kg body weight/hour, gradually increase by 2 mg/kg body weight/hour every 30 minutes if no signs of infusion-associated reactions occur up to a maximum of 7 mg/kg body weight body/hour.			
Generalities				
Analog of the human Acid Alpha Glucosidase enzyme, purified by recombinant DN ovary cell cultures. Alglucosidase Alfa acts on the underlying cause of Pompe dise malfunction of the enzyme Alpha Acid Glucosidase, indicated in the treatment of palate varieties.	ase, due to the deficiency, lack or			
Risk in Pregnancy C				
Adverse effects Vomiting, urticaria, erythema, maculopapular rash, facial redness, hypertension, pacyanosis, cough, tachypnea, pyrexia and chills.] allor, agitation, tremor, tachycardia,			
Contraindications and Precautions Contraindications: Hypersensitivity to the drug. Precautions: Anaphylactic reactions, infusion-associated reactions and patients with an advanced stage of Pompe disease.				

Interactions

No drug interaction studies have been performed with alglucosidase alfa. As it is a human recombinant protein, cytochrome P450-mediated drug interactions are unlikely to occur with alglucosidase alfa.

ALIROCUMAB

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Treatment of the	Subcutaneous.
		hypercholesterolemia	
	Each prefilled pen or prefilled syringe contains:	(heterozygous familial and non-	Adults:
		familial) in patients at very high	75 mg once every 2 weeks.
	Alirocumab 75 mg	cardiovascular risk who do not	For patients requiring greater LDL-C reduction (>60%) may start with 150 mg once every 2 weeks
	Airocumab 75 mg	achieve LDL-C goals, in addition	may start with 150 mg once every 2 weeks
		to the maximum tolerated dose of	
010.000.6087.01	Package with 2 pens prefilled with 1 mL of	statins and/or ezetimibe.	
	solution (75 mg/mL).		
010.000.6087.02	Package with 6 pens prefilled with 1 mL of		
	solution (75 mg/mL).		
010.000.6087.03	Package with 1 syringe prefilled with		
	1 mL of solution (75 mg/mL).		
	Package with 2 syringes prefilled with 1 mL of		
010.000.6087.04	solution (75 mg/mL).		
010.000.6087.05	Package with 6 syringes prefilled with 1 mL of		
010.000.0007.00	solution (75 mg/mL).		
	INJECTABLE SOLUTION		
	Each prefilled pen or prefilled syringe contains:		
	Alirocumab 150 mg		
010.000.6088.01	Package with 2 pens prefilled with 1 mL of		
	solution (150 mg/mL).		
010.000.6088.02	Package with 6 pre-filled pens	l	

	with 1 mL of solution (150 mg/mL).			
010.000.6088.03	Package with 1 syringe prefilled with			
	1 mL of solution (150 mg/mL).			
010.000.6088.04	Package with 2 syringes prefilled with 1 mL of			
	solution (150 mg/mL).			
010.000.6088.05	Package with 6 syringes prefilled with 1 mL of			
	solution (150 mg/mL).			
		0		
		Generalities		
	, ,	a ,	d specificity to the proprotein convertase	
	be 9 (PCSK9). By inhibiting the bindin hereby reducing LDL-C levels.	ng of PCSK9 to LDLR, alirocur	nab increases the number of LDLR available	
to remove LDL, ti	lereby reducing LDL-C levels.			
Risk in Pregr	Risk in Pregnancy b			
		A 1	7	
	1	Adverse effects		
	the injection site, signs and sympton nummular eczema, urticaria and hyp		t and pruritus.	
Hypersensitivity,		ersensitivity vascullus.	_	
Contraindications and Precautions				
Contraindications	: Hypersensitivity to the drug			
Precautions: It sh	ould be used with caution in patients	with severe renal and hepatic	insufficiency.	
Interactions				
Alirocumab is a biological drug, so no pharmacokinetic effects are anticipated with other medications or on cytochrome P450				

enzymes. Regarding the effects of other medications on alirocumab, it is known that statins and other lipid-lowering therapies increase the production of PCSK9, the target protein of alirocumab.

ATORVASTATIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hypercholesterolemia.	Oral.
	Each tablet contains: Atorvastatin calcium trihydrate equivalent to 20 mg of atorvastatin.	Hyperlipidemias.	Adults: 20 mg every 24 hours, increase the dose according to
010.000.5106.00	Package with 10 tablets.		response.
010.000.5106.01	Package with 30 tablets.		Maximum dose 80 mg/day.
-		O	7

Generalities L

It reduces plasma concentrations of cholesterol and lipoproteins, competitively inhibiting HMG-CoA reductase in the liver and increasing the number of hepatic receptors for LDL on the cell surface. Reduces LDL production.

Risk in Pregnancy	x
	Adverse effects
Constipation, flatulence, dyspepsia, abd	minal pain, headache, myalgia, asthenia and insomnia.
Contraindications: Hypersensitivity to the	Contraindications and Precautions drug, pregnancy and lactation, and active liver disease.
	Interactions
Antacids reduce the plasma concentration concentrations of digoxin. Fibrates increases increases and the second se	ns of atorvastatin and erythromycin increases them. Atorvastatin increases plasma use the risk of myopathy.

DEZAFIDRATE			
Clue	Description	Indications	Route of administration and dosage

ľ	TABLET	Hyperlipidemias.	Oral.
		nypenipidemias.	Adults:
	Each tablet contains:		200 to 300 mg every 12 hours, after food.
	Bezafibrate 200 mg.		
			Children:
010.000.0655.00	Package with 30 tablets.		5 to 10 mg/kg body weight/day, divided dose every 8
			hours.
			7
		Generalities	
			lysis of adipose tissue and reducing the
concentration of	free fatty acids. Increases plasma cle	earance of low-density chole	sterol.
Risk in Preg	x X		
	inancy x		
		Adverse effects	Г
Nausaa vomitin	ng, bloating, diarrhea, weight gain, hea		
Nausea, voiniui	g, bloating, diarmea, weight gain, hea		
	Contraind	lications and Precautions	Г
Contraindication	ns: Hypersensitivity to the drug, liver o		_ stonathy
Contrainuication	o. Hypersensitivity to the drug, liver o	a maney failure and cholecy:	stopanty.
	[Interactions	Г
Increases the ef	fect of oral anticoagulants. Increases	the effect of insulin and oral	hypoglycemic agents
	leot of oral antioougularity. Inoreases		nypogiyoonno ugonto.
CALCIUM			
Clue	Description	Indications	Route of administration and dosage
	EFFERVESCENT TABLET	Hypocalcemia.	Oral.
			A dutter
	Each tablet contains:		Adults:
	Calcium gluconate lactate 2.94 g. Calcium carbonate 300 mg. equivalent		500 to 1000 mg every 12 hours.
	to 500 mg of ionizable calcium.		Children.
	3 • • • • • • • • • • • • • • • • • • •		250 to 500 mg every 12 hours.
010.000.1006.00	Package with 12 tablets.		The tablets must be dissolved in 200 mL of water.
	1	L .	1
		Generalities	7
Essential electro	olyte that participates in the normal fur	nction of muscle and nerve	cells and in blood coagulation mechanisms
	s in the ossification of the bone matrix		-
Risk in Preg	gnancy C		
			-
		Adverse effects	
Gastrointestinal	disorders, hypercalcemia, nausea, co	onstipation and thirst.	
			7
	3	lications and Precautions	
Contraindication	ns: Hypersensitivity to the drug, hyper	calcemia, renal failure, hype	rcalciuria and kidney stones
			-
		Interactions	
	nd corticosteroids decrease intestinal	absorption. Decreases the t	herapeutic effect of calcium blockers.
Increases the ris	sk of digitalis toxicity.		
CALCITONIN			
Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Osteoporosis.	Intramuscular, subcutaneous or intravenous
			infusion.
	Each vial or vial with solution or lyophilisate	Hypercalcemia.	1 A.W.
	contains: Synthetic salmon calcitonin		Adults:
	50 IU.	Paget's disease.	Intramuscular and subcutaneous: 50 to 100 IU
010.000.5161.00	Container with 5 ampoules or vial bottles		every 24 hours or alternate days.

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Osteoporosis.	Intramuscular, subcutaneous or intravenous infusion.
	Each vial or vial with solution or lyophilisate contains: Synthetic salmon calcitonin	Hypercalcemia.	Adults:
	50 IU.	Paget's disease.	
010.000.5161.00	Container with 5 ampoules or vial bottles with diluent.		Intramuscular and subcutaneous: 50 to 100 IU every 24 hours or alternate days.
010.000.5161.01	Container with 6 ampoules or vial bottles with diluent.		Intravenous infusion: 5 to 10 IU/kg body weight/day.
010.000.5161.02	Container with 12 ampoules or vial bottles with diluent.		Administer diluted in intravenous solutions packaged in bottles of

			glass.	
		Generalities		
Hypocalcemic hormone, whose effects generally oppose those of parathyroid hormone, which produces direct inhibition of osteoclastic bone resorption.				
<u> </u>		•		
Risk in Pre	gnancy	С		
Adverse effects				
Vertigo, nausea	, vomiting, chills, hyporexia and w	eight loss. Erythema at the ir	njection site. Swelling of the	
hands.				
	Contr	aindications and Precautions		
Contraindication	ns: Hypersensitivity to the drug.		<u> </u>	
Precautions: Ke	eep refrigerated at a temperature b	petween 2 and 8 °C. Use imn	nediately as it does not contain	
conservatives.	· · · · · · · · · · · · · · · · · · ·	Interactions		
None of clinical		IIILEIACIIOIIS		
None of clinical	importance.			
CALCITRIC				
Clue	Description SOFT GELATIN CAPSULE	Indications Hypoparathyroidism.	Route of administration and dosage Oral.	
	Each capsule contains: Calcitriol 0.25 µg.	Renal osteodystrophy.	Adults:	
	Calolition 0.25 µg.		Initial 0.25 µg/day. Increase the dose over two to	
010.000.1095.00	Container with 50 capsules.		four weeks at intervals of 0.5 to 3 µg/day.	
			Children:	
			Initial: 0.25 µg/day. Increase the dose by	
			2 to 4 weeks at 0.25 to 2 intervals μg/day.	
		Generalities		
Most active form	n of vitamin D. In the body it is syr	thesized from cholecalcifero	l.	
Risk in Pre	gnancy	С		
Adverse effects				
Nausea, vomiting and hypercalcemia, which leads to generalized vascular calcification.				
Contraindications and Precautions				
Contraindications: Hypersensitivity to the drug or vitamin D and hypercalcemia.				
Precautions: Patients using digitalis.				
Interactions				
Antagonizes the therapeutic effect of calcium blockers. With thiazides the risk of hypercalcemia increases.				
CALCIUM CARBONATE / VITAMIN D3				
	Description TABLET	Indications Adjuvant in treatment	Route of administration and dosage Oral.	
Clue				
Clue	Each tablet contains:	of osteoporosis.		
Clue	Calcium carbonate 1666,670 mg equivalent	of osteoporosis.	Adults:	
Clue		ot osteoporosis.	Adults: 1 tablet twice a day with food.	
Clue	Calcium carbonate 1666,670 mg equivalent to 600 mg of calcium Cholecalciferol 6.2 mg equivalent to 400 IU	of osteoporosis.		
	Calcium carbonate 1666,670 mg equivalent to 600 mg of calcium Cholecalciferol 6.2 mg equivalent to 400 IU of Vitamin D3	of osteoporosis.		
Clue 010.000.6000.00	Calcium carbonate 1666,670 mg equivalent to 600 mg of calcium Cholecalciferol 6.2 mg equivalent to 400 IU	of osteoporosis.		
	Calcium carbonate 1666,670 mg equivalent to 600 mg of calcium Cholecalciferol 6.2 mg equivalent to 400 IU of Vitamin D3	Generalities		

It is found in the skeleton. For years there has been evidence that adequate calcium intake in the early stages of life prevents subsequent loss of bone mass in later stages.

Vitamin D is formed in the skin by exposure to ultraviolet rays, and plays an important role in the absorption of calcium, bone health, muscle performance, balance and risk of falls. It is responsible for regulating adequate levels of serum calcium and promoting proper intestinal absorption of the mineral.

Risk in Pregnancy	то		
Abdominal distension or pain, cons	Adverse effects tipation, diarrhea, belching, flatulence, nausea, vomiting. Hypercalciuria, nephrolithiasis.		
Contraindications and Precautions Contraindications: Hypersensitivity to the drug. Precautions: No studies have been conducted during pregnancy in humans, but no undesirable effects have been reported at therapeutic doses.			
	Interactions		

Calcium may reduce the oral absorption of antibiotics such as fluoroquinolones, tetracyclines, or levothyroxine or phenytoin. Calcium can reduce the response to calcium channel blockers and in high doses increases the risk of cardiac arrhythmias in digitalized patients. Intestinal calcium uptake can be decreased by the simultaneous intake of some foods such as spinach, rhubarb, bran, other cereals, milk and dairy products. Concomitant administration with estrogens may increase calcium absorption. It should not be administered with antacids containing magnesium.

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hyperparathyroidism	Oral.
		secondary in patients with	
	Each tablet contains:	Chronic Kidney Failure on	Adults:
	Cinacalcet 30 mg.	dialysis who are refractory to	
010.000.5835.00	Package with 30 tablets.	conventional therapy with parathyroid hormone levels	For Secondary Hyperparathyroidism: initial dose of 30 mg daily with titration every 2 to 4 weeks to a maximum
	TABLET	greater than 85 pmol/L or	of
			180 mg per day.
	Each tablet contains:	800 pg/mL, in whom	With food or shortly after eating. The tablets should
010.000.7124.00	Cinacalcet 60 mg.	parathyroidectomy is contraindicated.	be taken whole and not divided.
010.000.7124.00	Package with 30 tablets.		

Generalities

Calcimimetic agent, allosteric modulator of the calcium sensing receptor in the parathyroid gland, which increases sensitivity to calcium and reduces the secretion of parathyroid hormone and simultaneously decreases calcium, phosphorus and the calcium- phosphorus produc

calcium and reduce	s the secretion of parathyroid hormone and s	imultaneously decreases calcium,	phosphorus and the calcium- phosphorus product.
Risk in Pregr	nancy c		
		Adverse effects]
Nausea and vomiting] .		
	Contraindi : Hypersensitivity to the drug. itor serum calcium levels for symptoms	ications and Precautions s of hypocalcemia.]
CYP3A4 enzyme	inhibitors, and medications metabolize	Interactions ad by CYP2D6.]
CYSTEAMIN	IE Description	Indications	Route of administration and dosage

	CAPSULE	Treatment of confirmed	Oral.
		nephropathic cystinosis.	
	Each capsule contains:		Children up to 12 years:
	Cysteamine bitartrate equivalent to 150 mg of		1.30 g/m2 /day, divided into 4 doses per day.
	cysteamine		
			Patients over 12 years of age and weighing over 50 kg:
010.000.6125.00	Container with 100 capsules		
			2 g/day, divided into 4 doses per day.

Generalities

Cysteamine is a product of the alimentary tract and metabolism, code ATC.A16AA04.6. Normal individuals and people heterozygous for cystinosis have leukocyte cystine levels < 0.2 and usually less than 1 nmol hemicystin/mg of protein, respectively. Individuals with nephropathic cystinosis present an elevation of leukocyte cystine above 2 nmol hemicystine protein. Cysteamine reacts with cystine giving rise to a mixture of cysteamine disolphide and cysteine, in addition to cysteine. The disolphide mixture is then removed from lysosomes by an intact lysine transporter system. The decrease in lucocyte cystine levels correlates with the plasma cysteamine concentration during the six hours following

Cysteamine administration

Risk in Pregnancy

Adverse effects

х

Abnormalities in liver function tests, Leukopenia, Headache, encephalopathy, drowsiness, seizures, vomiting, nausea, diarrhea, abdominal pain, bad breath, dyspepsia, gastroenteritis, gastrointestinal ulcer, nephrotic syndrome, hair color change, anorexia, asthenia, unpleasant skin odor, rash, lethargy, fever

Contraindications and Precautions

Contraindications: Hypersensitivity to the Drug. Patients who have presented hypersensitivity to penicillamine. Precautions: For maximum benefit, Cysteamine therapy should be initiated promptly upon confirmation of the diagnosis of nephropathic cystinosis. Nephropathic cystinosis must have been diagnosed through clinical examinations such as biochemical evaluations (leukocyte cystine level measurements).

Interactions

It can be used together with electrolyte and mineral supplements necessary in the treatment of Falconi syndrome, as well as vitamin D and thyroid hormones. Indomethacin has been administered concomitantly with Cysteamine in certain patients. Patients undergoing kidney transplantation have used treatments to prevent rejection along with cysteamine.

DAPAGLIFLOZIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Diabetes treatment	Oral.
		mellitus type 2 when metformin	
	Each tablet contains:	therapy does not provide adequate	Adults:
	Dapagliflozin propanediol	glycemic control.	10 mg every 24 hours
	equivalent to 10 mg		Take in combination with metformin.
	of dapagliflozin	The stars at s6 h s at 6 it as with	
		Treatment of heart failure with	
010.000.6007.00	Package with 14 tablets.	reduced ejection fraction.	
010.000.6007.01	Package with 28 tablets.		
	Ū.	Treatment of chronic kidney disease	
		with glomerular filtration rate of	
		25 to	
		75 mL/min/1.73 m2 with and	
		without diabetes	
		without diabetes	<u> </u>

Generalities

Dapagliflozin is the first sodium-glucose co-transporter 2 (SGLT2) inhibitor approved in Mexico, it is characterized by being highly selective and reversible, it represents the first drug in its class due to its mechanism of action. SGLT2 is selectively expressed in segment 1 of the proximal convoluted tubule of the kidney and is responsible for reabsorbing 90% of filtered glucose. Dapagliflozin improves fasting and postprandial plasma glucose concentrations by reducing renal glucose reabsorption, resulting in urinary excretion of glucose (glycosuria).

Risk in Pregnancy

Adverse effects

с

Genital and urinary infections. The frequency of hypoglycemia depends on the type of concomitant therapy (insulin or sulfonyulrea).

	8	Contraindications	and Precautions	
--	---	-------------------	-----------------	--

Contraindications: Hypersensitivity to the drug.

Precautions: In patients at risk of hypoglycemia and on insulin and/or sulfonylurea therapy. The efficacy of Dapagliflozin depends on renal function, it should not be used in patients with moderate to severe renal impairment (defined as eGFR <45 mL/min/1.73m2 by MRHD or CrCl <60 mL/min by Cockcroft-Gault), no not for safety reasons but for a decrease in effectiveness.

Interactions

The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide conjugation. In studies in healthy subjects, the pharmacokinetics of dapagliflozin were not altered by metformin, pioglitazone (a [major] substrate of CYP2C8 and [secondary] of CYP3A4), sitagliptin (a substrate of hOAT-3 and P-glycoprotein), glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan or simvastatin. A 22% decrease in systemic exposure of dapagliflozin following coadministration with rifampicin was considered not large enough to justify a dose adjustment.

DEFLAZACORT

Clue	Description	Indications	Route of administration and dosage
	TABLET	Inflammatory processes	Oral.
	Each tablet contains:	severe and autoimmune.	Adults:
	Deflazacort 6 mg.		
010.000.4505.00	Package with 20 tablets.		Initial: 6-120 mg per day, depending on the severity of the clinical condition.
	TABLET		
			Support: 18 mg per day, which should be
	Each tablet contains:		adjusted according to clinical response.
	Deflazacort 30 mg.		
010.000.4507.00	Package with 10 tablets.		Children:
	SUSPENSION		0.25-2 mg per day, although it will depend on the severity of the clinical condition and should be
	Each mL of suspension contains: Deflazacort 22.75 mg.		adjusted according to the clinical response.
010.000.4509.00	Container with glass bottle with 13 mL of suspension and dropper.		

Generalities

Oxazoline derivative of the glucocorticoid prednisolone, with immunomodulatory and anti-inflammatory properties.

Risk in F	reananc
-----------	---------

Adverse effects

b

Systemic gastrointestinal, metabolic and nutritional, central and peripheral nervous system, psychiatric and skin disorders.

Contraindications: Hypersensitivity to the drug.

Contraindications and Precautions

Interactions

With cardiac glycosides or diuretics, the risk of hypokalemia increases.

DENOSUMAB

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Intolerant	Subcutaneous.
		postmenopausal women	
	Each prefilled syringe contains:	to	Adults:

010.000.5613.00	Denosumab 60 mg. Package with a prefilled syringe with 1 mL.	oral bisphosphonates, with previous fracture and high risk of fracture.	60 mg once every six months.		
		Generalities	1		
Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the activation of its receptor, RANK, on the surface of osteoclast precursors and in osteoclasts. Preventing the RANKL/RANK interaction inhibits the formation, function, and survival of osteoclasts, which in turn causes decreased bone resorption in trabecular and cortical bone.					
Risk in Pregnancy c					
Urinary tract infectior	n, upper respiratory tract infection, sciatica,	Adverse effects cataracts, constipation, rash, pain in ex] tremities.		
Contraindications and Precautions Contraindications: Hypersensitivity to the drug. Precautions: Hypocalcemia. Patients receiving Denosumab may develop skin infections (mainly cellulitis) requiring hospitalization.					
		Interactions			
No interaction studie	s have been performed.				

DESMOPRESSIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Nocturnal enuresis.	Oral.
	Each tablet contains:		Children from 6 to 12 years of age:
	Desmopressin acetate equivalent to 60 µg		Initial dose: 120 µg at bedtime, sublingually,
	of desmopressin.		every 24 hours.
010.000.5690.00	Package with 30 tablets.		If necessary, the dose can be increased
	TABLET		to 240 µg. It should be accompanied by
			nocturnal fluid restriction.
	Each tablet contains:		
	Desmopressin acetate equivalent to 120		
	µg of desmopressin.		
010.000.5691.00	Package with 30 tablets.		
	TABLET	Diabetes insipidus.	Oral.
	Each tablet contains:		Adults and children:
	Desmopressin acetate 0.2 mg	Primary enuresis.	Adults and children:
	equivalent to 178 µg of		100 to 200 µg of desmopressin acetate every
	desmopressin.		24 hours, before bedtime.
	deshipressin.		
010.000.1099.00	Package with 30 tablets.		
	NASAL SOLUTION		Intranasal.
	Each mL contains:		Adults:
	Desmopressin acetate equivalent to 89 µg		From 5 to 40 µg/day, every 8 hours.
	of desmopressin.		
			Children from 3 months to 12 years:
010.000.1097.00	Nebulizer container with 2.5 mL.		5 to 30 µg daily in one dose.
	INJECTABLE SOLUTION		Intravenous.
	Each vial contains:		Adults:
	Desmopressin Acetate 15 µg.		0.3 µg body weight. It can be repeated after 6 hours
	Desmopresan Acetate 13 µg.		0.5 µg body weight. It can be repeated after 6 hours
010.000.5169.00	Container with 5 vials with one mL.		

Generalities
Vasopressin analogue that increases the permeability of the convoluted tubules and promotes water reabsorption, producing
an increase in urine osmolarity and a decrease in urine volume. Increases the von factor

Willebrand and shortens the bleeding time.

Risk in Pregnancy b
Adverse effects
Abdominal pain, nausea, facial flushing during administration, paleness and headache.
Contraindications and Precautions Contraindications: Hypersensitivity to the drug, von Willebrand disease type lib, coronary heart disease, high blood pressure hemophilia and nasal congestion.
Interactions Carbamazepine, chlorpropamide and non-steroidal anti-inflammatory drugs increase their antidiuretic effect.

DEXAMETHASONE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Allergic diseases.	Oral.
	Each tablet contains	Inflammatory	Adults:
	Dexamethasone 0.5 mg.	diseases.	Initial: 0.25 to 4 mg/day, divided every 8 hours.
010.000.3432.00	Package with 30 tablets.	Addison's disease.	Maintenance: 0.5 to 1.5 mg/day, divided every 8 hours. The dose should be reduced gradually until the desired
		Bronchial asthma.	therapeutic effect is achieved.
			Children:
			0.2 to 0.3 mg/kg body weight/day, divided every 8 hours.
2			
		Generalities	1
Glucocorticoid the	at inhibits phospholipase A2 and therefo	pre inhibits the synthesis of p	roteins, thromboxanes and leukotrienes.

Glucocorticold that inhibits phospholipase A2 and therefore inhibits the synthesis of proteins, thromboxanes and leuko

Risk in Pregnancy

Adverse effects

Cataract, Cushing's syndrome, obesity, osteoporosis, gastritis, superinfections, glaucoma, hyperglycemia, muscle hypercatabolism, delayed healing and growth retardation

с

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Systemic mycosis. Precautions: Peptic ulcer, high blood pressure, DM 1 and DM 2, liver and kidney failure, immunosuppression, therapy with thiazides and furosemide.

		In	teractions	
 day and	1		and a function for a first of the	

Alcohol and non-steroidal anti-inflammatory drugs increase gastrointestinal adverse effects. Ephedrine, phenobarbital and rifampin decrease the therapeutic effect.

ELOSULPHASE ALPHA

BLE SOLUTION	Treatment of mucopolysaccharidosis IV	Intravenous.
	mucopolysaccharidosis IV	
contains:	type A (Morquio A	Children and adults:
e alfa 5 mg	syndrome, MPS IV-A).	2 mg per kg of body weight administered once a week as an intravenous infusion
with a vial with 5 mL (5 mg/5 mL).		over a minimum period of 3.5 to 4.5 hours, based on the volume of the infusion.
	Ŭ	e alfa 5 mg syndrome, MPS IV-A).

Elosulfase Alfa is a purified human enzyme, produced by recombinant DNA technology in a Chinese hamster ovarian cell line. Human N-acetylgalactosamine-6-sulfatase is a glycosaminoglycan-specific lysosomal hydrolytic enzyme that hydrolyzes galactose sulfate-6-sulfate or N-acetyl-galactosamine-6-sulfate in the

non-reducing ends of the keratan sulfate (KS) and chondroitin-6-sulfate (C6S) glycosaminoglycans					
Diels in Dreamoney	c				

Risk in Pregnancy

Adverse effects

Pyrexia, vomiting, headache, nausea, abdominal pain, chills and fatigue.

Contraindications and Precautions

Interactions

Contraindications: Hypersensitivity to the drug.

Precautions: Patients with acute febrile respiratory illness may be at high risk of fatal complications due to hypersensitivity reactions. Careful consideration should be given to the clinical status of the patient prior to administration.


No drug interactions have been observed.

EMPAGLIFLOZIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Treatment of	Oral.
		type 2 diabetes mellitus when	Adults:
	Each tablet contains:	metformin therapy does not	10 mg once a day. Patients who have successfully
	Empagliflozin 10 mg	provide adequate	tolerated 10 mg and require additional glycemic control
		glycemic control.	the dose may be increased to 25 mg once daily.
010.000.6008.00	Package with 30 tablets.		
	TABLET		
			Take in combination with metformin.
	Each tablet contains:		
	Empagliflozin 25 mg		
010.000.6009.00	Package with 30 tablets.		

Generalities

Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for the reabsorption of glucose from the glomerular filtrate, returning it to the circulation. Empagliflozin is an SGLT2 inhibitor, and therefore reduces glucose reabsorption and increases the amount of glucose eliminated in the urine. The action of empagliflozin is independent of the function of pancreatic beta cells and insulin secretion and therefore the risk of producing hypoglycemia is very low. The excretion of glucose in the urine results in a loss of calories, which is associated with a loss of body fat and weight loss.



Vaginal moniliasis, vulvovaginitis, balanitis and other genital infections. Urinary tract infection. Hypoglycemia (when used with a sulfonylurea or insulin). Pruritus (generalized). Hypovolemia. Increased urination, dysuria.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Treatment with empagliflozin should not be initiated in patients with an eGFR less than 60 mL/min/1.73 m2 or CrCl <60 mL/min. Treatment with empagliflozin should be discontinued when eGFR is consistently below 45 mL/min/1.73 m2 or CrCl is consistently below 45 mL/min.

Empagliflozin is not effective in patients undergoing dialysis.

Due to its mechanism of action, mainly renal, it is advisable to monitor renal function before starting treatment with empagliflozin and at periodic intervals. Likewise, if other drugs that may affect kidney function are added, this will be adequately monitored.

The fall in volume induced by osmotic diuresis that accompanies glycosuria may affect hydration status, particularly in elderly patients, with a decrease in anterior pressure. Caution should be used in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on antihypertensive treatment with a history of hypotension, or patients 75 years of age or older. . In the case of concomitant diseases that may lead to fluid loss (e.g. diarrhea), close monitoring of blood volume and electrolytes is recommended.

Increased glucose concentrations in the urine can promote infections (cystitis, balanitis, pyelonephritis, urethral sepsis, etc.). In the case of patients with complicated urinary tract infections, temporary interruption of treatment with empagliflozin should be considered.

Interactions

Loop and thiazide diuretics may increase the risk of dehydration and hypotension. No clinically significant interactions were observed when empagliflozin was co-administered with other commonly used medicinal products.

EMPAGLIFLOZIN/METFORMIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Treatment	Oral
	Each tablet contains: Empagliflozin 12.5 mg metformin hydrochloride 850 mg	complementary to diet and exercise regimen for glycernic control in adults with type 2 diabetes mellitus	Adults One tablet twice a day.
010.000.6077.00	Package with 60 tablets.	2 who already receive Empagliflozin and metformin co- administered as tablets with each drug separately.	Dosage should be individualized based on the patient's current regimen, effectiveness and tolerance, without exceeding the maximum recommended daily dose of 25 mg of empagliflozin and 2000 mg of metformin.

Generalities

Empagliflozin is a competitive, selective, reversible and highly potent inhibitor of SGLT-2, with an IC50 value of 1.3 nM. It has 5000 times greater selectivity against human SGLT-1 (IC50 of 6278 nM), responsible for glucose absorption in the intestines. High selectivity was also demonstrated for other glucose transporters (GLUT) responsible for glucose homeostasis in different tissues.

Metformin is a biguanide with antihyperglycemic effects, which reduces both basal and postprandial plasma glucose values. This drug does not stimulate insulin secretion and, therefore, does not cause hypoglycemia.

Risk in Pregnancy

d

Adverse effects Urinary tract infection, vaginal moniliasis, vulvovaginitis, balanitis, frequency, polyuria, nocturia, decreased blood pressure

(ambulatory), decreased systolic blood pressure, dehydration, hypotension, hypovolemia, orthostatic hypotension, syncope,

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs. Moderate to severe kidney failure. Patients > 75 years of age.

Precautions: This product contains lactose so patients with rare hereditary diseases of galactose intolerance, e.g. g., galactosemia, they should not take this medication. Insulin and secretagogues Insulin, such as sulfonylureas, may increase the risk of hypoglycemia. Therefore, a dose may be required of insulin or an insulin secretagogue to reduce the risk of hypoglycemia when used in combination with empagliflozin.

isulin of an insulin secretagogue to reduce the risk of hypoglycemia when used in combination with empaglifi

Interactions	

The effect of empagliflozin may add to the diuretic effect of thiazide diuretics and loop diuretics, and may increase the risk of dehydration and hypotension. Empagliflozin does not inhibit, inactivate or induce CYP450 isoenzymes. There is an increased risk of lactic acidosis in the event of acute alcohol poisoning, so the consumption of alcohol and medicinal products containing alcohol should be avoided. Cationic agents that are eliminated by renal tubular secretion (e.g., cimetidine) may interact with metformin by competing for renal tubular transport systems that are common to both. Intravascular administration of iodinated contrast media can lead to renal failure, which could result in accumulation of metformin and the risk of development of lactic acidosis.

EVOLOCUMAB

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Primary hypercholesterolemia	Subcutaneous.
		(heterozygous familial	
	Each prefilled syringe contains:	and non-familial) and mixed	Adults:
	Evolocumab 140 mg	dyslipidemia in patients with	140 mg every 2 weeks.
		high cardiovascular risk who,	
010.000.6089.00	Container with a syringe prefilled with 1 mL of	despite being treated with	
	solution (140 mg/mL).	statins	

010.000.6089.01 Package with a pre-filled pen		high intensity, not reach target LDL-C levels.				
with 1 mL of solution (140 mg/mL	with 1 mL of solution (140 mg/mL).					
		O	_			
, l		Generalities				
Evolocumab is a human IgG2 monoclonal antibody		•				
preventing PCSK9 and prevents the binding of circulate preventing PCSK9-mediated degradation of LDLR. I	•	• • • • • • •	DLR) located on the cell surface of the liver, thereby			
	h					
Risk in Pregnancy	b					
I	A	Adverse effects	7			
Nasopharyngitis, upper respiratory tract in	fection. back	pain, arthralgia, flu, and nau	」 Jsea.			
	,	· · · · · · · · · · · · · · · · · · ·				
[Contraindi	cations and Precautions				
Contraindications and precautions: Hypersensitivity to the drug. Hypersensitivity to latex.						
r		Interactiona	7			
No formal durin durin interaction attacks	Interactions					
No formal drug-drug interaction studies ha	ive been per	formed for Evolucumab.				

EXENATIDA

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Diabetes mellitus type 2.	Subcutaneous.
	Each mL contains:		Adults and people over 18 years of age: Home
	Exenatide 250 µg.		
010.000.4169.01			5 µg every 12 hours for one month.
010.000.4169.01	Pen container with 10 µg/dose (60 doses/2.4		Maintenance.
	mL).		
			10 µg every 12 hours from the second month of treatment.
	INJECTABLE SUSPENSION		Subcutaneous.
	EXTENDED RELEASE		Caboulanoodol
			Adults and people over 18 years of age:
	Each prefilled pen contains:		2 mg once a week.
	Exenatide 2 mg		
	5		
010.000.6054.01	Package with 4 single-dose cases. Each case		
	contains: 1 pen prefilled with powder and 0.65 mL		
	of diluent for needle suspension. A spare needle.		

Generalities

Glucagon-like peptide 1 (GLP-1). Incretin mimetic agent that increases glucose-dependent insulin secretion and simulates other antihyperglycemic actions of incretins. Peptide amine 39 amino acids with MW of 4186.6 Daltons.

Risk in Pregnancy

Adverse effects

С

Diarrhea, dyspepsia, gastroesophageal reflux disease, nausea, vomiting, asthenia, feeling nervous, decreased appetite, dizziness, headache, hyperhidrosis. Risk of pancreatitis in patients with hyperlipidemia. Risk of renal failure with concomitant use with nephrotoxic drugs and in patients dehydrated due to gastroenteritis or use of diuretics.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and type 1 diabetes mellitus. Precautions: Exenatide is not a substitute for insulin in patients who require it. It should not be used in patients with diabetic ketoacidosis. It should also not be used in patients with type 2 diabetes who require insulin therapy due to beta cell failure. Oral or intravenous hydration in patients dehydrated before of exenatide use.

Interactions

The decreased rate of gastric emptying as an effect of exenatide may reduce the extent and rate of absorption of orally administered medications. It should be used with caution in patients receiving oral medications that require rapid gastrointestinal absorption. The AUC and Cmax of lovastatin were decreased by approximately 40% and 28%, respectively, and the Tmax was delayed by about 4 hours when exenatide (10 ÿg BID) was administered concomitantly with single dose lovastatin (40 mg) compared to lovastatin administered alone. In a clinical pharmacology study in healthy volunteers, a delay of approximately 2 hours in Tmax was observed when warfarin was administered 30 minutes after exenetide.

EZETIMIBA

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hypercholesterolemia.	Oral.
	Each tablet contains:		Adults:
	Ezetimibe 10 mg.		
010.000.4024.00	Package with 7 tablets.		10 mg per day, alone or combined with a statin.
010.000.4024.01	Package with 10 tablets.		
010.000.4024.02	Package with 14 tablets.		
010.000.4024.03	Package with 21 tablets.		
010.000.4024.04	Package with 28 tablets.		
010.000.4024.05	Package with 30 tablets.		
		Generalities	
It acts on the villi	of the small intestine, inhibiting	the absorption of cholesterol.	_
Risk in Prea	hancy	С	
_			
		Adverse effects	7

Angioedema, diarrhea, abdominal pain, arthralgia, fatigue, back pain and cough.

Contraindications and Precautions
e drug.
Interactions

With cyclosporine it increases its levels.

EZETIMIBA-SIMVASTATINE

Clue	Description	Indications	Route of administration and dosage
	COMPRESSED	Hypercholesterolemia	Oral.
		primary.	
	Each tablet contains: Ezetimibe 10		Adults:
	mg.		
	Simvastatin 20 mg.		One tablet every 24 hours, at night.
010.000.4025.00 010.000.4025.01	Package with 14 tablets. Package with 28 tablets.		

Generalities

Ezetimibe acts on the villi of the small intestine by inhibiting cholesterol absorption. Simvastatin is an inactive lactone that *in vivo* is rapidly transformed by hydrolysis into the corresponding b-hydroxy acid, which is a potent inhibitor of HMG-CoA reductase.

Risk in Pregnancy

Adverse effects

With ezetimibe frequently abdominal pain, diarrhea, fatigue, flu-like symptoms, muscle cramps; Rarely cutaneous and subcutaneous disorders, hypersensitivity reactions including angioneurotic edema and rash.

With simvastatin frequently anemia, abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting, pancreatitis, hepatitis-jaundice, muscle cramps, myopathy, rhabdomyolysis, paresthesias, peripheral neuropathy, alopecia, pruritus, rash. Rarely, hypersensitivity syndrome such as angioneurotic edema, lupoid syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, increased erythrocyte sedimentation rate, arthritis and arthralgia, urticaria, photosensitivity, fever, flushing, dyspnea and general malaise.

Contraindications and Precautions

Contraindications: Hypersensitivity to any of the components of the medication. Active liver disease or unexplained persistent elevation of serum transaminases. Pregnancy and breastfeeding. Precautions: In mild liver failure. Discontinue immediately in case of significant increase in

liver enzymes (hepatitis) and muscle enzymes (myopathy, rhabdomyolysis).

In	teractions

Ezetimibe does not induce cytochrome P-450 drug-metabolizing enzymes. No clinically important interaction has been observed between ezetimibe and drugs that are metabolized by cytochromes P-450 1A2 2D6 2C8 2C9 and 3A4 or by acetyltransferase. Simvastatin is metabolized by CYP3A4 but does not inhibit its activity; Therefore, it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Strong CYP3A4 inhibitors increase the risk of myopathy by decreasing the elimination of the simvastatin component (Itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, cyclosporine). With diltiazem, amiodarone, verapamil, gemfibrozil and niacin, the risk of myopathy increases. Antacids and cholestyramine decrease the absorption of ezetimibe.

FENOFIBRATE

Clue	Description	Indications	Route of administration and dosage
	CAPSULE	Reduction in progression	Oral.
		of proliferative diabetic retinopathy	
	Each capsule contains:	No patients with in	Adults:
	Fenofibrate 200 mg	type 2 diabetes mellitus.	200 mg or 160 mg every 24 hours with food
010.000.6134.00	Container with 14 capsules.		
010.000.6134.01	Container with 28 capsules.	Hypercholesterolemia and	
3	·	Hypertriglyceridemia alone or	
	CAPSULE	combined as well as dyslipidemia	
		type III and V	
	Each capsule contains:		
	Fenofibrate 160 mg		
010.000.6276.01	Box with 30 capsules.		

Generalities

Derived from fibric acid whose lipid-modifying effects reported in humans are mediated through the activation of the Peroxisome Proliferated Activated Receptor, type alpha (PPARÿ).

Through activation of PPARÿ, fenofibrate increases lipolysis and clearance of atherogenic triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing apoprotein CIII production. These effects of fenofibrate on lipoproteins lead to a reduction in very low and low density ("VLDL") fractions.

and "LDL") that contain apoportein B and an increase in the fraction of high-density lipoprotein (HDL) that They contain apoproteins AI and AII.

Risk in Pregnancy

х

Adverse effects

Abdominal pain, nausea, vomiting, diarrhea, flatulence, increased transaminases, increased homocysteine levels.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen; in cases of liver and/or kidney damage; as well as in the presence of known gallbladder disease and/or chronic pancreatitis.

Precautions: Before considering fenofibrate therapy, the secondary cause of hyperlipidemia should be treated such as: uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, drug treatment, alcoholism. For patients with hyperlipidemia taking estrogens or estrogen-containing contraceptives, it should be confirmed whether the hyperlipidemia is primary or secondary in nature (possible increase in lipid values caused by oral estrogens).

Interactions

Fenofibrate increases the effect of the oral anticoagulant and may increase the risk of bleeding. It is advisable to reduce the dose of anticoagulants by approximately one third at the beginning of treatment and then gradually adjust it, if necessary, based on INR monitoring.

Some severe cases of reversible deterioration of renal function have been reported during concomitant administration of fenofibrate and cyclosporine. Therefore, the renal function of these patients should be closely monitored.

patients and suspend treatment with fenofibrate in case of severe alteration of laboratory parameters. The risk of severe muscle disease is increased if a fibrate is used concomitantly with HMG-CoA reductase inhibitors or other fibrates. This combination therapy should be used with caution and patients should be closely monitored for evidence of muscle toxicity. Some cases of paradoxical reversible reduction of HDL cholesterol have been reported during concomitant administration of fenofibrate and glitazones. Therefore, it is recommended to monitor HDL cholesterol when one of these components is added to the other and suspend any of the therapies when HDL cholesterol is very low.

Patients with co-administration of fenofibrate and drugs metabolized by CYP2C, CYP2A6 and, especially, CYP2C9 with a reduced therapeutic index, should be carefully monitored and it is advisable, if necessary, to adjust the dose of these drugs.

FLUDROCORTISONE

Description	Indications	Route of administration and dosage
COMPRESSED	Insufficiency	Oral.
	chronic adrenocortical.	
Each tablet contains: Fludrocortisone		Adult:
acetate 0.1 mg.	Adrenogenital syndrome with	
	salt loss.	100 µg every 24 hours; decrease to 50 µg every 24
Package with 100 tablets.		hours, if high blood pressure occurs.
		Children:
		50 to 100 µg every 24 hours.
	COMPRESSED Each tablet contains: Fludrocortisone acetate 0.1 mg.	COMPRESSED Insufficiency chronic adrenocortical. Each tablet contains: Fludrocortisone acetate 0.1 mg. Adrenogenital syndrome with salt loss.

Generalities

Synthetic glucocorticoid with very high mineralocorticoid activity and moderate glucocorticoid activity. С

Risk in Pregnancy

Adverse effects

Arterial hypertension, anaphylactic reaction, vertigo, congestive heart failure, severe headache, hypokalemia and peripheral edema.

Contraindications and Precautions

Contraindications: Hypersensitivity to fludrocortisone.

Precautions: Consider risk benefit in patients with congestive heart failure, high blood pressure, impaired kidney function, during pregnancy and lactation. Treatment should not be stopped abruptly.

Interactions

With digitalis it can cause cardiac arrhythmias. With diuretics the hypokalemic effect is intensified.

FLUVASTATIN

Clue	Description	Indications	Route of administration and dosage	
	CAPSULE Each capsule contains: Fluvastatin sodium equivalent to 20 mg fluvastatin.	Hypercholesterolemia primary.	Oral. Adults: 20 to 40 mg every 24 hours, at night.	
010.000.4244.01	Container with 28 capsules.			
Competitive inhib	itor of HMG-CoA reductase, with greate	Generalities er effect in reducing LDL.]	
Adverse effects Constipation, nausea, flatulence, dyspepsia, abdominal pain, headache, myalgia, asthenia and insomnia.				
Contraindications: Hypersensitivity to the drug, pregnancy, lactation and active liver disease. Precautions: Therapeutic with fibrates and niacin.				
		Interactions		
Cimetidine, ranitidine and omeprazole increase the bioavailability of fluvastatin. Rifampin decreases it.				

GALSULPHASE

INJECTABLE SOLUTION		
INJECTABLE SOLUTION	replacement therapy	Intravenous.
	enzymatic for	
Each vial contains: Galsulfase 5 mg.	Mucopolysaccharidosis VI	Children, adolescents and adults
	(Maroteaux-Lamy	1.0 mg/Kg of body weight, once a week, administered in
	Disease).	solution over 4 hours.
Package with a vial with 5 mL (1 mg/mL).		
		Galsulfase should be diluted in 0.9% saline, to a total
		volume of 250 mL. In subjects weighing < 20 kg susceptib
		to fluid overload, the total volume can be reduced to 100
		mL.
		It is recommended to administer 2.5% of the volume in
		the first hour, and the remaining 97.5% over the following
		three hours.
		Each vial contains: Galsulfase 5 mg. Mucopolysaccharidosis VI (Maroteaux-Lamy Disease).

Galsulfase has been developed with the purpose of offering a treatment for MPS VI, by replacing the deficient enzyme, Nacetylgalactosamine 4-sulfatase (aryl sulfatase B), thereby reducing the abnormal accumulation of GAG that is the cause of the deleterious effects to the disease.

Risk in Pregnancy



Adverse effects

Pharyngitis, gastroenteritis, areflexia, conjunctivitis, corneal opacity, otalgia, hypertension, dyspnea, apnea, nasal congestion, abdominal pain, umbilical hernia, facial edema, chest pain, tremors, general malaise.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Sleep apnea is common in patients with MPS VI, and prior treatment with antihistamines may increase the risk of apnea episodes. Assessment of airway patency should be considered before initiation of treatment. Patients using oxygen or continuous positive airway pressure

airways during sleep should have these devices readily available during the infusion, in the event of a

possible reaction or excessive drowsiness/sleepiness induced by the use of antihistamine.

In MPS VI, symptoms related to airway obstruction and anatomical characteristics such as craniofacial alterations, short neck, stiffness of the faciocervical joints, and anterolaterally positioned larynx are factors that complicate laryngoscopy and intubation. A careful evaluation of the cardiovascular and respiratory system is required before performing procedures such as sedation or anesthesia; An otolaryngologist should be involved in these procedures.

Interactions

No interaction studies have been performed, nor have they been identified in clinical experience with the product.

CHORIONIC GONADOTROPHIN

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Ovulation inducer in case of	Intramuscular or subcutaneous.
		female infertility.	
	Each vial or vial with lyophilisate contains:		Adults:
			Women: 5,000 to 10,000 IU, one day after the last dos
	Chorionic gonadotropin 5,000 IU.	Hypogonadism.	of urophyllotropin or 5 to
			12 days after the last dose of clomiphene.
010.000.1081.00	Container with 1 vial and vial with 2 mL of diluent.	Cryptorchidism not obstructive.	
			Men: 1,000 to 4,000 IU three times a week
010.000.1081.01	Package with 1 or 3 ampoules or vials	Feminine infertility.	week
	and 1 or 3 ampoules with		for 3 to 9 months.
	1 mL of diluent.	Hypogonadism.	
			Children:
		Hypogonadotrophic.	1,000 to 5,000 IU every third day.
	INJECTABLE SOLUTION		Administer 4 doses.
			Subcutaneous.
	Each vial with lyophilisate contains:		
			Women with anovulation or oligoovulation:
	Chorionic gonadotrophin 250 ÿg.		
			250 ÿg 24-48 hours after the last application of FSH o
010.000.1081.02	Container with a vial with lyophilisate and a vial		after the last dose of clomiphene, when optimal
	or vial with 1 mL of diluent.		stimulation of development has been achieved

-				
				follicular.
				Women undergoing assisted reproduction techniques:
				250 ÿg 24-48 hours after the last FSH application, when optimal stimulation of follicular development has been achieved.
				Hypogonadotrophic hypogonadism:
				250 ÿg twice a week alternating with FSH (75 to 150 IU) three times to stimulate week. For Spermatogenesis requires 12 weeks of treatment.
1				
Hormone substit Leydig.	ute that stimulates	1	Generalities re follicle and the production] n of androgens in the cells of the
Risk in Preg	nancy	с		
			1	7
Pain at the inject	ion site, precocious		dverse effects e, irritability, depression.	J
i ani at the inject				r i
Contraindications androgen-dependent			cations and Precautions v and gonadal tumors, ovaria] an dystrophy, precocious puberty and
			Interactions]
With luteinizing h	ormone and follicle	stimulating ovulation	on is promoted.	
ICATIBANT				
Clue	Descr	Infion	Indications	Boute of administration and depage
Clue	Descr INJECTABLE SOLUTION	-	Indications Symptomatic treatment	Route of administration and dosage Subcutaneous, in the abdominal area.
Clue	INJECTABLE SOLUTION Each prefilled syringe co Icatibant acetate equivale	ntains:		-
010.000.5990.00	INJECTABLE SOLUTION	ntains: ent to	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1	Subcutaneous, in the abdominal area. Adults and people over 18 years of age.
	INJECTABLE SOLUTIOI Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled :	ntains: ent to syringe with 3 mL	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency.	Subcutaneous, in the abdominal area. Adults and people over 18 years of age.
010.000.5990.00 Synthetic decape	INJECTABLE SOLUTION Each prefilled syringe co Icatibant acetate equivale 30 mg icatibant Package with a prefilled s (10 mg/mL).	N ntains: ent to syringe with 3 mL -proteinogenic amir	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency.	Subcutaneous, in the abdominal area. Adults and people over 18 years of age.
010.000.5990.00 Synthetic decape	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bra	N ntains: ent to syringe with 3 mL -proteinogenic amir adykinin.	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency.	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg.
010.000.5990.00 Synthetic decape receptor, with a s	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bra	N ntains: ent to syringe with 3 mL -proteinogenic amir adykinin.	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency.	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg.
010.000.5990.00 Synthetic decape receptor, with a s	INJECTABLE SOLUTION Each prefilled syringe co lcatibant acetate equivale 30 mg icatibant Package with a prefilled i (10 mg/mL). eptide with five non- similar affinity to brain nancy	N ntains: ent to syringe with 3 mL -proteinogenic amir adykinin. ;	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg.
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bran nancy c ction, pyrexia, eleva s: Hypersensitivity t ing acute coronary	N ntains: ent to syringe with 3 mL -proteinogenic amir adykinin. c ated transaminases Contraindig o the drug.	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness.
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bran nancy c ction, pyrexia, eleva s: Hypersensitivity t ing acute coronary	N ntains: ent to syringe with 3 mL -proteinogenic amir adykinin. c ated transaminases Contraindig o the drug.	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects a, nervous system disorders, cations and Precautions	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness.
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur Cerebral Vascula	INJECTABLE SOLUTION Each prefilled syringe co leatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bran nancy c ction, pyrexia, eleva s: Hypersensitivity to ing acute coronary ar.	N ntains: ent to syringe with 3 mL proteinogenic amir adykinin. e Contraindia o the drug. ischemia, unstable	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects a, nervous system disorders. Cations and Precautions angina, or in the weeks foll Interactions	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness. owing an accident
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur Cerebral Vascula	INJECTABLE SOLUTION Each prefilled syringe co leatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bran nancy c ction, pyrexia, eleva s: Hypersensitivity to ing acute coronary ar.	N ntains: ent to syringe with 3 mL proteinogenic amir adykinin. e Contraindia o the drug. ischemia, unstable	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities to acids. Selective competiti dverse effects a, nervous system disorders. cations and Precautions angina, or in the weeks foll	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness. owing an accident
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur Cerebral Vascula	INJECTABLE SOLUTION Each prefilled syringe co leatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bran nancy c ction, pyrexia, eleva s: Hypersensitivity to ing acute coronary ar.	N ntains: ent to syringe with 3 mL proteinogenic amir adykinin. e Contraindia o the drug. ischemia, unstable	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects a, nervous system disorders. Cations and Precautions angina, or in the weeks foll Interactions	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness. owing an accident
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur Cerebral Vascula Metabolic drug intera	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bra nancy c ction, pyrexia, eleva s: Hypersensitivity t ing acute coronary ar.	N ntains: ent to syringe with 3 mL proteinogenic amir adykinin. e Contraindia o the drug. ischemia, unstable	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects a, nervous system disorders. Cations and Precautions angina, or in the weeks foll Interactions	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness. owing an accident
010.000.5990.00 Synthetic decape receptor, with a s Risk in Preg Injection site read Contraindications Precautions: Dur Cerebral Vascula	INJECTABLE SOLUTION Each prefilled syringe co loatibant acetate equivale 30 mg icatibant Package with a prefilled : (10 mg/mL). eptide with five non- similar affinity to bra nancy c ction, pyrexia, eleva s: Hypersensitivity t ing acute coronary ar.	N ntains: ent to syringe with 3 mL proteinogenic amir adykinin. ented transaminases Contraindid o the drug. ischemia, unstable coetween Icatibant and C	Symptomatic treatment of acute attacks of hereditary angioedema (HAE), with C1 esterase inhibitor deficiency. Generalities no acids. Selective competiti dverse effects a, nervous system disorders. Cations and Precautions angina, or in the weeks foll Interactions	Subcutaneous, in the abdominal area. Adults and people over 18 years of age. 30 mg. ive antagonist of the bradykinin B2 dizziness. owing an accident

	INJECTABLE SOLUTION	Hunter syndrome	Intravenous infusion.		
	Each vial contains: Idursulfase 6 mg.	(Mucopolysaccharidosis II).	Adults and children 5 years of age and older:		
			0.5 mg/Kg of body weight, administered weekly.		
010.000.5550.00	Container with vial bottle with 3 mL (6 mg/3 mL).		Dilute in 100 mL of 0.9% sodium chloride solution.		
			Manage in a period of 1 to 3 hours.		
-		Generalities	- -		
Idursulfase is a p	urified form of the lysosomal enzyme		u functions to catabolize the		
			ate groups linked to the oligosaccharides.		
Risk in Pregnancy c					
		Adverse effects]		
Difficulty breathing, hypoxia, hypotension, seizure, loss of consciousness, angioedema of the throat or tongue, hypertension, dyspepsia, urticaria, rash, pruritus.					
	Contraine	lications and Precautions			
Contraindications: Hypersensitivity to the medication. Precautions: Patients with severe underlying respiratory tract disease.					
		Interactions	1		
No formal drug ir	No formal drug interaction studies have been performed.				

IMIGLUCERase

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Gaucher disease	Intravenous infusion.
		non-neuropathic (Type I)	
	Each vial with powder contains:		Children, adolescents and adults:
		Chronic neuropathic disease	60 U/kg of body weight, once every 2 weeks, in the first
	Imiglucerase 400 U.	(Type III) due to deficiency of the enzyme	months.
		Glucocerebrosidase.	Then adjust the dose according to the patient's response to treatment.
010.000.5545.00	Container with vial bottle with lyophilized powder.		to treatment.
			For neuropathic or type III Gaucher disease, 120 U/kg of
			body weight, once every 2 weeks, and up to 240
			U/Kg of body weight, once every 2
			weeks.
			Administer diluted in 0.9% sodium chloride intravenous
			solutions, packaged in glass bottles (dilute the reconstituted
			dose in a volume of 100 to 200 mL).
			Administer the solution for 1 to 2 hours. Speed not
			exceeding 1 unit per kg of body weight per minute.
•			
		Generalities	

Enzyme analogue of the human glucocerebrosidase enzyme, Imiglucerase, purified by recombinant DNA technology using live Chinese hamster ovary cell cultures. Imiglucerase acts on the underlying cause of Gucher's disease Type I and III, due to the deficiency, lack or malfunction of the enzyme Glucocerebrosidase which catabolizes the hydrolysis of glycolipids (glucosyl-ceramide).

Risk	in F	, veu	nancv	

Adverse effects

Nausea, vomiting, abdominal pain, diarrhea, dizziness, headache, paresthesia, tachycardia, cyanosis, facial redness, hypotension, respiratory symptoms and arthralgia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Severe allergic-type hypersensitivity reactions. Patients who have developed antibodies or symptoms of hypersensitivity to Imiglucerase.

Interactions

HUMAN C1 ESTERASE INHIBITOR

No interaction studies have been performed.

Clue	Description	Indications	Route of administration and dosage
010.000.6055.00	INJECTABLE SOLUTION Each vial contains: Human C1 esterase inhibitor 500 IU Container with vial bottle with lyophilisate and vial bottle with 10 mL of diluent.	Hereditary angioedema (HAE) due to INH- C1 deficiency types 1 and 2. Treatment of acute episodes.	Intravenous. Adults and children over 3 years of age: 20 IU/Kg of body weight.

Generalities

The C1 esterase inhibitor belongs to the inhibitory system of serine proteases (serpins) in human plasma, like other proteins such as antithrombin III, alpha-2-antiplasmin, alpha-1-antitrypsin and others.

Risk in Pregnancy



с

Elevation of temperature, reactions at the injection site, tachycardia, flushing, ueticaria, dyspnea, headache, dizziness and nausea. Development of thrombosis in treatment attempts with high doses for the prophylaxis or treatment of Capillary Drip Syndrome before, during or after cardiac surgery according to extracorporeal circulation.

	Contraindications and Precautions		
Contraindications: Hypersensitivity to the biological.			
	Interactions		
N			

No interaction studies have been performed.

ASPARTIC INSULIN AND/OR ASPARTE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Mellitus diabetes.	Intravenous or subcutaneous.
	Each mL contains: Insulin aspartic and/or aspart (recombinant DNA origin)		Adults:
	100 IU.		Dose according to the patient's requirement 3 or more times a day.
010.000.4156.01	Pre-filled pen with 3 mL.		

Insulin aspart is identical to natural human insulin, causes rapid transport of glucose and amino acids from the cell, promotes the uptake and storage of glucose in the form of glycogen in the liver, inhibits gluconeogenesis, promotes the conversion of excess glucose in fats.

Risk in Pregnancy

		D

Adverse effects

Allergic reactions, lipodystrophy and hypoglycemia.

Contraindications and Precautions

Contraindications: hypersensitivity to the drug, hypoglycemia.

Precautions: Inappropriate dosing or discontinuation of treatment, especially in type 1 patients, leads to hyperglycemia and diabetic ketoacidosis. Skipping a meal or engaging in unplanned exercise Strenuous exercise can lead to hypoglycemia.

INSULIN ASPARTA / INSULIN ASPARTA PROTAMINE)

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SUSPENSION	Mellitus diabetes.	Subcutaneous.
	Each mL contains:		Adults:
	Insulin aspart of recombinant DNA origin (30% soluble insulin aspart and		Dosage according to the patient's needs.
	70% crystalline protamine insulin aspart) 100 U		In type 2 diabetes mellitus it can be administered as monotherapy or in combination with oral antidiabetics. The initial dose is 6 U with breakfast and
010.000.6117.01	Container or cardboard box with 5 prefilled or prefilled pens with 3 mL (100 U/		6 U with snack. It is also possible to start treatment by administering
	mL).		12 U once a day.
			In type 1 diabetes mellitus, the individual insulin need is usually between 0.5 to
			1.0 U/Kg of body weight/day.

Generalities

The blood glucose-lowering effect of insulin occurs when the molecules facilitate glucose uptake by binding to insulin receptors on muscle and fat cells, while inhibiting glucose production by the liver.

Insulin aspart containing 30% soluble insulin aspart, which begins to act quickly, and 70% insulin aspart crystallized with protamine, which has an activity profile similar to that of human NPH insulin.

Risk in Pregnancy	С
	Adverse effects
Hypoglycemia, urticaria, rashes, rash, c	liabetic retinopathy, lipodystrophy, edema.
	Contraindications and Precautions
Contraindications: Hypersensitivity to th Precautions: Hypoglycemia.	e biological.
	Interactions

The following substances may reduce the patient's insulin requirements: oral antidiabetics (ADOs), angiotensin-converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulfonamides.

The following substances may increase the patient's insulin requirements: oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.

Beta blockers may mask hypoglycemic symptoms. Octreotide/lanreotide can either increase or decrease insulin requirements. Alcohol consumption can intensify or reduce the effects

insulin hypoglycemia.

INSULIN DEGLUDEC

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION Each mL contains: Insulin degludec (DNA origin recombinant) 100 U	Diabetes mellitus type 1 in adolescents and children from 1 year of age.	Subcutaneous 100 units/mL a dose of 1-80 units can be administered per injection, in steps of 1 unit. It is administered once a day.
010.000.6316.00	Cardboard box with 1 pre-filled pen with 3 mL.		
010.000.6316.01	Each cardboard with 5 pens prefilled with 3 mL.		

Generalities

Ultra-long-acting basal insulin to be used once a day at any time of the day.

It specifically binds to the human insulin receptor and results in the same pharmacological effect as human insulin. The blood glucose-lowering effect of this insulin is due to facilitated glucose uptake following binding of insulin to receptors in muscle and fat cells and simultaneous inhibition of glucose production in the liver.

Risk in Pregnancy		b
	Adverse effects	

Immune system disorders, hypoglycemia, lipodystrophy, injection site reactions.

Contraindications and Precautions Contraindications:

hypersensitivity to the active substance or to any of the excipients. Precautions: hypoglycemia, hyperglycemia, effects on the ability to drive and use machinery.

Interactions	

Substances that reduce the need for insulin: Oral antidiabetic medicinal products, GLP-1 receptor agonists, monoamine oxidase inhibitors (MAOIs), beta blockers, angiotensin-converting enzyme (ACE) inhibitors, salicylates, steroids, anabolics and sulfonamides.

Substances that may increase insulin requirements: oral contraceptives, thiazides, glucocorticoids, thyroid hormones, growth hormone, danazol.

Beta blockers can mask the symptoms of hypoglycemia.

Octreotide/Lanreotide may increase or decrease insulin requirements.

Alcohol can intensify or reduce the hypoglycemic effect of insulin.

INSULIN DETEMIR

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Mellitus diabetes.	Subcutaneous.
	Each mL contains:		Adults:
	Insulin detemir (insulin analogue of recombinant DNA origin) 100 U.		Dose: according to the patient's requirement.
010.000.4165.00	Container or cardboard box with 1 prefilled or prefilled pen with 3 mL (100 U/mL).		
010.000.4165.01	Container or cardboard box with 5 prefilled pens. or prefilled with 3 mL (100 U/mL).		

Generalities

Insulin detemir is derived from human insulin by deletion of the B30 residue and acylation of the Lys series-side amino group. ^{B29} by the natural occurrence of tetradecanoic fatty acid. The prolonged action of insulin is mediated by self-association of its molecules to the injection site and albumin binding via the fatty acid side chain. The absorption rate is limited by the low concentration of insulin available by diffusion through the tissue and passage through the capillary wall.

Risk in Pregnancy

b

Adverse effects Cold sweating, pale skin, feeling of fatigue, nervousness, anxiety, tremor, confusion, excessive feeling of hunger, temporary changes in vision, headache, nausea and tachycardia.

Contraindications and Precautions

Contraindications: Patients with hypoglycemia, history of hypersensitivity to the components of the formula.

Interactions The hypoglycemic effect may be increased by: oral hypoglycemic agents, MAO inhibitors, alcohol, non-selective beta-blocking agents, ACE inhibitors, salicylates, sulfonamides, octreotide.

The hypoglycemic effect can be reduced by: oral contraceptives, thiazides, corticosteroids, thyroid hormones, sympathomimetics and danazol.


INSULIN GLARGINE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Diabetes mellitus type 1	Subcutaneous.
	Each mL of solution contains: Insulin glargine 3.64 mg equivalent to	Diabetes mellitus type 2.	Adults:
	100.0 IU of human insulin.		Once a day, at night.
			The dose must be adjusted individually at the discretion of the specialist.
010.000.4158.00	Container with a vial bottle with 10		

010.000.4158.01	mL. Container with 5 glass cartridges with 3 mL in disposable device.		
Generalities Analogue of human insulin that has low solubility at neutral pH. At acidic pH (pH 4) it is completely soluble. After subcutaneous injection, the acid solution is neutralized, causing the formation of microprecipitates from which small amounts of insulin glargine are continuously released, giving rise to a uniform concentration without peaks with a prolonged duration of action.			
Risk in Pres	gnancy b		
Adverse effects Allergic reactions, lipodystrophy, hypokalemia and hypoglycemia. Contraindications and Precautions Contraindications: Hypersensitivity to insulin glargine or any of the components of the formula. Precautions: Kidney and liver failure. Beta blockers mask the symptoms of hypoglycemia.			
	-	nteractions	7
and sulfonamide danazol, diazoxio progestogens, pr hypoglycemic eff	s, ACE inhibitors, salicylates, disopyrami antibiotics may increase the hypoglycen de, diuretics, glucagon, isoniazid, somato	ide, fibrates, fluoxetine, M nic effect and susceptibilit otropin phenothiazine deri otic medications such as c ts and alcohol can enhance	vatives, thyroid hormones, estrogens and planzapine and clozapine can reduce the se or weaken the hypoglycemic effect.

INSULIN LISPRO

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION.	Diabetes mellitus type 1.	Subcutaneous.
	Each mL contains: Insulin lispro (DNA origin recombinant) 100 IU.		Adult and children: The dose is established according to the patient's needs.
010.000.4162.00	Container with a 10 mL vial.		



Insulin analogue, with the same stability as regular human insulin, but with much faster absorption, which provides it with a more physiological profile.

Risk in Pregnancy

b

Adverse effects

Allergic reactions, lipodystrophy, hypokalemia and hypoglycemia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and hypoglycemia.

Precautions: Kidney and liver failure. Beta blockers mask the symptoms of hypoglycemia.

Interactions

Oral contraceptives, corticosteroids and thyroid hormones reduce the hypoglycemic effect. Salicylates, sulfonamides and inhibitors of monoamine oxidase and angiotensin-converting enzyme and increase the hypoglycemic effect.

INSULIN LI	SPRO.	LISPRO	PROTAMINE

Clue	Description	Indications	Route of administration and dosage

	INJECTABLE SUSPENSION	Insulin-dependent diabetes	Subcutaneous.
		mellitus.	
	Each mL contains:		Adults:
	Insulin lispro (DNA origin		At the discretion of the specialist doctor and in
	recombinant) 25 IU		accordance with the patient's needs.
	Insulin lispro protamine (DNA origin		
	recombinant) 75 IU		
010.000.4148.01	Container with a 10 mL vial.		
	·		-
		Generalities	
Insulin analogue	with the same stability as regular hu	iman insulin, but with much fa	aster absorption, which provides it with a
more physiologic	al profile.		
	•		
Risk in Pre	phancy b		
	gnanoy		
		Adverse effects	7
AU			
Allergic reactions	s, lipodystrophy, hypokalemia and hy	pogiycemia.	
			-
	Contraine	dications and Precautions	
Contraindication	s: Hypersensitivity to the drug, hypog	lycemia.	
Precautions: Kid	ney and liver failure. Beta blockers m	ask the symptoms of hypogly	vcemia.
		, , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		Interactions	7
Ouel			

Oral contraceptives, corticosteroids and thyroid hormones reduce the hypoglycemic effect. Salicylates, sulfonamides and monoamine oxidase and angiotensin-converting enzyme inhibitors increase the hypoglycemic effect.

LANREOTIDA

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Acromegaly and tumors neuroendocrine.	Deep subcutaneous.
	Each prefilled (ready to use) syringe		Adults:
	contains:		Acromegaly.
	Lanreotide acetate equivalent to		60 to 120 mg every 28 days. Neuroendocrine tumors.
	90 mg lanreotide:		Initial dose: 60 to 120 mg every 28 days.
			If the response is insufficient, the dose can be adjusted
010.000.5610.00	Package with a prefilled syringe with 0.3 mL.		to
010.000.5610.01	Package with a 0.5 mL prefilled syringe with		120 mg every 28 days. Extended treatment:
	safety device.		In patients well controlled with somatostatin analogues,
			they can be treated with lanreotide 120 mg every 42 or 56 days.
	INJECTABLE SOLUTION	1	
	Each prefilled (ready to use) syringe contains:		The injection must be administered by a health professional.
			However, for patients treated for acromegaly or
	Lanreotide acetate equivalent to		neuroendocrine tumors who receive a continuous stable
	120 mg lanreotide		dose, the product can be administered by the patient or
010.000.5611.00			by a trusted person with prior training from a healthcare
010.000.5611.00	Package with a prefilled syringe with 0.5 mL.		professional.
010.000.5611.01	Package with a 0.5 mL prefilled syringe with		
	safety device.		
	L	I a	
		Generalities	7

Lanreotide is an octapeptide analogue of human somatostatin. Like natural somatostatin, Lanreotide is an inhibitor of various exocrine and paracrine endocrine functions. Lanreotide is much more active than natural somatostatin and has a much longer duration of action.

Risk in Pregnancy

Adverse effects

Fatigue, headache, vertigo, bradycardia, hypoglycemia and hyperglycemia, diarrhea, abdominal pain, nausea, vomiting, dyspepsia, flatulence, acute pancreatitis, steatorrhea, gallstones, increased bilirubin, anemia, weight loss.

С

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Lanreotide may reduce gallbladder motility and cause gallstones. Patients should be monitored frequently.

Patients treated with Lanreotide Autogel may experience hypoglycemia or hyperglycemia. Slight decreases in thyroid function have been observed during treatment in patients with acromegaly. Caution should be exercised when initiating treatment with lanreotide in patients with bradycardia.

Interactions	

Insulin, oral hypoglycemic medications, cyclosporine. Lanreotide acetate may reduce intestinal absorption of concomitantly administered drugs.

.

LARONIDASE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Disease of Mucopolysaccharidosis Type I	Intravenous infusion.
	Each vial contains: Laronidase 2.9 mg (500 U).	due to deficiency of the enzyme Alpha-L-	Children, adolescents and adults: 0.58 mg (100 U)/kg body weight, once every week.
		Iduronidase.	0.50 mg (100 0)/kg body weight, once every week.
010.000.5547.00	Container with vial with 5 mL (2.9 mg or 500 U).		Administer diluted in intravenous solutions of 0.9%
	,		sodium chloride, packaged in glass bottles (bring the
			reconstituted dose to a volume of 100 mL if the patient's weight is \ddot{y} 20 kg or 250 mL if the patient's weight is \ddot{y} 20
			kg).
			Initial rate of 0.0116 mg (2 U)/kg body/hour, increase weight gradually every 15 minutes, if
			tolerated, to a maximum of 0.2494 mg (43
			U)/kg body weight/hour.
			Total administration time 3-4 hours.
	1		I I

Generalities

Enzyme analogue of the human enzyme alpha -L-Iduronidase, Laronidase, purified by DNA technology recombinant using live Chinese hamster ovary cell cultures. Laronidase acts on the underlying cause of Mucopolysaccharidosis Type I disease, due to the deficiency, lack or malfunction of the enzyme Alpha-L-Iduronidase which catabolizes the hydrolysis of glycominiglycans from heparan sulfate and dermatan sulfate.

Risk in Pregnancy	С	
	Adverse effects	
Abdominal pain, headache, rash, o	dyspnea, arthralgia, back pain, tachycardia, pyrexia, ch	ills.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Precautions: Reactions associated with infusion and readministration after stopping treatment.

Interactions

No interaction studies have been performed. Chloroquine or procaine due to the risk of interference with intracellular reuptake of lanoridase. Risk of interference with the intracellular uptake of laronidase: with chloroquine and procaine.

LEVOTHYROXINE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hypothyroidism.	Oral.
	Each tablet contains: Levothyroxine sodium equivalent to 100 µg levothyroxine sodium		Adults: Dose: 50 μg/day, increase at intervals of 25 to 50 μg a day for two to four

1	anhydrous.		weeks until the therapeutic effect is achieved. Maximum dose 200 µg/day.			
010.000.1007.00	Package with 100 tablets.		Children:			
			From 6 months 8 to 10 µg /kg body weight/day.			
			From 6 to 12 months 6 to 8 µg/kg body weight/day.			
			From 1 to 5 years: 5 to 6 µg/kg body weight/day.			
			From 6 to 12 years: 4 to 5 µg/kg body weight/day.			
I	l		Administration is as a single dose.			
		Generalities				
Thyroid hormone	Thyroid hormone that intervenes in protein metabolism and body and brain development.					
Risk in Pregnancy TO						
Adverse effects						
Tachycardia, cardiac arrhythmias, angina pectoris, nervousness, insomnia, tremor, weight loss and menstrual irregularities.						
Contraindications and Precautions						
Contraindications: Adrenal insufficiency, hyperthyroidism, euthyroidism, acute myocardial infarction. Precautions: Cardiovascular disease, diabetes mellitus and diabetes insipidus.						

Interactions

.

Phenytoin, acetylsalicylic acid, adrenergics, tricyclic and digitalis antidepressants increase its effect. Cholestyramine decreases it.

Γ

LEVOTHYROXINE SODIUM

Clue	Description	Indications	Route of administration and dosage
	TABLET	For the treatment of	Oral.
		hypothyroidism.	
	Each tablet contains:		Adults:
	Levothyroxine sodium 25 µg		Mild hypothyroidism: initial dose 50µg/day, increasing every 2 to 4 weeks until the desired dose is obtained.
010.000.6169.00	Package with 50 tablets.		
			Patients with sudden onset of hypothyroidism can be
			administered initial doses of 100 to 200 µg/day.
			maintenance dose of 100 to 200
			µg/day (1.7 µg/Kg body weight/day) although some
			patients may require higher doses.
			Severe hypothyroidism: initial dose of
			12.5-25 µg/day, increasing from 25 to 50 µg/day at intervals of 2 to 4 weeks until adequate
			response is obtained.
			Children
			Maintenance dose:
			From 0 to 3 months 10-15 µg/kg body weight/day.
			From 3 to 6 months 25-50 µg per day or 8-10
			μg/Kg body weight/day.
			From 6-12 months 50-75 µg per day or 6-8 µg/Kg body weight/day.
			μg/Kg body weight/day. From 1-5 years old 75-100 μg per day or 5-6 μg/Kg of
			body weight/day.
			From 6-12 years 100-150 µg per day or 4-5
			μg/Kg body weight/day.
			After 12 years ÿ 150 µg per day or 2-3
			μg/Kg body weight/day.
		Generalities	7
The maint is a second	a that intervenes in protein matchaliam		

Thyroid hormone that intervenes in protein metabolism and body and brain development.

Adverse effects

Cardiac arrhythmias, tachycardia, palpitations, anguina pectoris, headache, muscle weakness, cramps, flushing, fever, vomiting, menstruation disorders, pseudotumor cerebri, tremor, restlessness, insomnia, hyperhidrosis, weight loss, diarrhea, fatigue, increased appetite, heat intolerance, hyperactivity, anxiety, irritability, emotional lability, increased blood pressure, heart failure, heart attack, colic, hair loss, angioedema.

Contraindications and Precautions

Contraindications: Adrenal insufficiency, untreated pituitary insufficiency, subclinical thyrotoxicosis, acute myocardial infarction, acute myocarditis or acute pancarditis.

Precautions: Coronary insufficiency, anguina pectoris, arteriosclerosis, hypertension, pituitary insufficiency or adrenal insufficiency, psychotic disorders, coronary insufficiency, heart failure or arrhythmias due to tachycardia. In postmenopausal women.

Interactions

Antidiabetic medications, coumarin derivatives, phenytoin, salicylates, dicumarol, furosemide, clofibrate, orlistat, sevelamer, tyrosine kinase inhibitors, ion exchange resins, aluminum iron and calcium salts, propylthiurasil, glucocorticoids, betasympatholytics, and contrast media containing iodine, amiodarone, sertraline, chloroquine/proguanil, enzyme inducers such as barbiturates, medicinal products leading to liver enzyme induction, estrogens, ferrous sulfate, 5-fluorouracil, tamoxifen, tri/tetracyclic antidepressants.

LINAGLIPTIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Adjuvant treatment from Type 2 diabetes	Oral.
	Each tablet contains:	mellitus, to failure of	Adults:
	Linagliptin 5 mg.	metformin and sulfonylureas.	5 mg every 24 hours. Single, fixed dose, as monotherapy or in combination
010.000.5621.00	Package with 30 tablets.		treatment with metformin, sulfonylureas, thiazolidinediones.

Generalities

Inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase 4), an enzyme that participates in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide). Both incretin hormones participate in physiological regulation. of glucose homeostasis.

Risk in Pregnancy

С

Adverse effects

Hypoglycemia, nausea, vomiting, vertigo.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: It should not be used in patients with Type 1 Diabetes, nor for the treatment of diabetic ketoacidosis. Hypoglycemia.

Interactions

Clinical data suggest that the risk of clinically significant interactions with co-administered medicinal products is low. No clinically significant interactions requiring dose adjustment were observed.

Linagliptin had no clinically relevant effects on the pharmacokinetics of metformin, glibenclamide, simvastatin, Pioglitazone, warfarin, Digoxin, or oral contraceptives, providing in vivo evidence of a low propensity to cause drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and the organic catatonic transporter.

LINAGLIPTIN/METFORMIN

	Clue	Description	Indications	Route of administration and dosage
1				

010.000.5740.00	TABLET Each tablet contains: Linagliptin 2.5 mg Hydrochloride Metformin 500 mg Package with 60 tablets.	Type 2 diabetes mellitus, in patients who do not respond to metformin alone, or as a substitute in those who are under treatment and achieve good control with the free combination of linagliptin and metformin.	Oral. Adults. 2.5/500mg every 12 hours.
010.000.5741.00	TABLET Each tablet contains: Linagliptin 2.5 mg Hydrochloride Metformin 850 mg. Package with 60 tablets.		2.5/850mg every 12 hours.
010.000.5742.00	TABLET Each tablet contains: Linagliptin 2.5 mg Hydrochloride Metformin 1000 mg Package with 60 tablets.		2.5/1000mg every 12 hours.

Generalities

Linagliptin-metformin combines two antihyperglycemic drugs with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase inhibitor

 $4 \ (\mbox{DDP-4})$ and metformin hydrochloride, a member of the biguanide class.

Risk in Pregnancy

С

Adverse effects

The most frequently reported adverse reaction for linagliptin plus metformin was diarrhea (0.9%) with a rate comparable to that of metformin plus placebo (1.2%). Hypoglycemia may occur when Linagliptin-metformin is administered together with a sulfonylurea (ÿ 1 case in 10 patients). In the analysis of pooled placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo was similar to that of those treated with linagliptin 2.5 mg and metformin (50.6% and 47.8%). Treatment discontinuation due to adverse events was similar in patients receiving placebo and metformin and those receiving linagliptin and metformin (2.6% and 2.3%).

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs. It should not be used in patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.

Precautions: Diabetic precoma, renal failure (creatinine clearance <60 mL/minute), acute conditions that may alter renal function: dehydration, severe infection, shock, intravascular administration of

iodinated contrast, acute or chronic illness that can cause hypoxia: cardiac or respiratory failure, recent myocardial infarction, liver failure, acute alcoholism and alcoholism, lactic acidosis and hypoglycemia when Linagliptin-metformin is administered together with a sulfonylurea.

Interactions	

Clinical data suggest that the risk of clinically significant interactions with co-administered medicinal products is low. Linagliptin had no clinically relevant effects on the pharmacokinetics of metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin or oral contraceptives, providing in vivo evidence of a low propensity to cause drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, glycoprotein P and the organic cationic transporter.

With metformin there is a greater risk of lactic acidosis in cases of acute alcoholism. Cationic agents that are eliminated by secretion from the renal tubules such as cimetidine may interact with metformin. Intravascular administration of iodinated contrast agents for radiological studies may cause insufficiency.

kidney, and risk of lactic acidosis; Therefore, it should be discontinued before or at the time of the study, and for the next 48 hours, and resume when kidney function has been reassessed and determined its normality.

LIRAGLUTIDE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Type 2 diabetes mellitus, in patients with failure to 2 oral	Subcutaneous.
	Each milliliter contains:	agents, and who have a	Adults.
	Liraglutide (recombinant DNA)	BMI > 35	Starting dose: 0.6 mg once daily for 7 days.
	6 mg.	Kg/m2 , before the use of insulin.	Maintenance dose: 1.2 mg once daily.
010.000.5743.00	Package with 2 pens with a 3 mL cartridge.		

Generalities

Liraglutide is a GLP-1 analog with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target of native GLP-1, an endogenous incretin hormone that enhances glucose-dependent insulin secretion in pancreatic beta cells. Unlike native GLP-1, liraglutide has a human pharmacokinetic and pharmacodynamic profile suitable for once-daily administration. Following subcutaneous administration, the delayed action profile is based on three mechanisms: self-association, resulting in slow absorption; binding to albumin and superior enzymatic stability with respect to dipeptidyl peptidase IV (DPP-IV) and the enzyme neutral endopeptidase (NEP), resulting in a prolonged plasma half-life.

Risk in Pregnancy

d

Adverse effects

Gastrointestinal disorders: nausea and diarrhea were very common, while vomiting, constipation, abdominal pain and dyspepsia were common. At the start of Liraglutide therapy, these gastrointestinal adverse reactions may occur more frequently. These reactions usually decrease after a few days or weeks of continued treatment. Headache and nasopharyngitis were also common.

In addition, hypoglycemia was found to be common, and very common if Liraglutide is used in combination with a sulfonylurea. Severe hypoglycemia has been observed primarily when combined with a sulfonylurea.

Very few cases of acute pancreatitis have been reported during long-term clinical studies with Liraglutide.

A causal relationship between Liraglutide and pancreatitis cannot be established or excluded.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. It should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Cautions: Liraglutide is not a substitute for insulin. The addition of liraglutide to the treatment of patients already using insulin has not been studied and therefore this use is not recommended. Experience in patients with New York Heart Association (NYHA) class I and II congestive heart failure is limited. There is no experience in patients with NYHA class II and IV congestive heart failure. Experience in patients with inflammatory bowel disease and diabetic gastroparesis is limited, therefore the use of Liraglutide in these patients is not recommended. The use of Liraglutide is associated with transient gastrointestinal adverse reactions, such as nausea, vomiting and diarrhea. Thyroid adverse events have been reported in clinical trials including increased blood calcitonin, goiter, and thyroid neoplasia, especially in patients with pre-existing thyroid disease. Patients receiving Liraglutide in combination with a sulfonylurea may be at increased risk of hypoglycemia. It is possible to reduce the risk of hypoglycemia by reducing the dose of sulfonylurea. Signs and symptoms of dehydration including renal insufficiency and acute renal failure have been reported in patients receiving Liraglutide. Patients receiving Liraglutide should be advised that there is a potential risk of dehydration related to gastrointestinal adverse effects and to take precautions to avoid fluid loss.

Interactions

In vitro, liraglutide has demonstrated a very low potential to be involved in pharmacokinetic interactions with other active substances related to cytochrome P450 and plasma protein binding. The slight delay in gastric emptying associated with liraglutide may influence the absorption of concomitant oral medications. Interaction studies have not demonstrated any clinically significant delay in absorption.

Few patients treated with liraglutide reported at least one episode of severe diarrhea. Diarrhea may influence the absorption of concomitant oral medications. No interaction studies have been performed with warfarin and other coumarin derivatives, so more frequent INR monitoring is recommended. No pharmacokinetic and pharmacodynamic interactions were observed between liraglutide and insulin determir.

METFORMIN/ GLIBENCLAMIDE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Diabetes mellitus type 2.	Oral.
	Each tablet contains:		Adults.
	Metformin hydrochloride 500 mg.		2 tablets per day during the main meal, without exceeding
	Glibenclamide 2.5 mg		2 g of metformin per day, later this daily dose may be
010.000.6273.00	Package with 30 tablets.		reduced at the doctor's discretion.
010.000.0273.00	Fackage with 50 tablets.		
		Generalities	7

Metformin. Biguanide that increases the peripheral effect of insulin and decreases gluconeogenesis. Glibenclamide.

Oral hypoglycemic agent derived from sulfonylureas that stimulates the activity of the beta cells of the pancreas, promoting insulin.

release of the

Risk in Pregnancy	d		
	Adve	erse effects	1
Hypoglycemia, urticaria, fatigue, we hypoplasia, gastrointestinal intolera			hepatitis, hemolytic anemia and spinal taste and lactic acidosis.

Contraindications and Precautions

Glibenclamide. Contraindications: Hypersensitivity to the drug and sulfonamide derivatives. Diabetes mellitus type 1, kidney failure, pregnancy and lactation. Metformin. Contraindications: Hypersensitivity to the drug, type 1 diabetes mellitus. diabetic ketoacidosis, kidney failure, liver failure, heart or lung failure, severe malnutrition, chronic alcoholism and acute alcohol poisoning. Pregnancy and lactation.

Interactions

Glibenclamide. Cyclophosphamide, oral anticoagulants, beta blockers and sulfonamides increase its hypoglycemic effect. Adrenergic corticosteroids, thiazide diuretics and furosemide decrease its hypoglycemic effect. A disulfiram-type reaction occurs with ethyl alcohol. Metformin. Decreases the absorption of vitamin B12 and folic acid. Sulfonylureas promote the hypoglycemic effect. Cimetidine increases the plasma concentration of metformin


METFORMIN/GLIMEPYRIDE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Diabetes mellitus type 2.	Oral.
	Each tablet contains:		Adults.
	Metformin hydrochloride 500 mg.		
	Glimepiride 1 mg		1 tablet a day. Make gradual adjustments to determine the
			effective dose for each patient.
010.000.6274.00	Package with 32 tablets.		
010.000.0274.00	Fachage with 52 lablets.		


Generalities

Metformin. Biguanide that increases the peripheral effect of insulin and decreases gluconeogenesis. Glimepiride. It regulates insulin secretion by interacting with the ATP-sensitive potassium channel in pancreatic beta cells.

Risk in Pregnancy	d



Hypoglycemia, urticaria, fatigue, weakness, headache, nausea, diarrhea, reactive hepatitis, hemolytic anemia and spinal hypoplasia, gastrointestinal intolerance, headache, transient skin allergies, metallic taste and lactic acidosis.



Hypersensitivity to the drug, type 1 diabetes mellitus, diabetic ketoacidosis, kidney failure, liver failure, heart or lung failure, severe malnutrition, chronic alcoholism and acute alcohol poisoning. Pregnancy and lactation

Interactions

Metformin. Decreases the absorption of vitamin B12 and folic acid. Sulfonylureas promote the hypoglycemic effect. Cimetidine increases the plasma concentration of metformin

METFORMIN/LINAGLIPTIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Diabetes mellitus type 2.	Oral.
	Each tablet contains: Metformin Hydrochloride 500 mg		2.5 mg linagliptin and 500 mg metformin twice daily.
010.000.5740.01	Linagliptin 2.5 mg Package with 30 tablets.		The maximum dose is 5 mg linagliptin and 2000 mg of metformin.

Generalities

Metformin. Biguanide that increases the peripheral effect of insulin and decreases gluconeogenesis. Linagliptin. DPP-4 enzyme inhibitor enzyme that participates in the inactivation of the incretin hormones GLP-1 and GIP, both incretin hormones participate in the physiological regulation of glucose taxis.

Risk in Pregnancy

Adverse effects

с

Hypoglycemia, urticaria, fatigue, weakness, headache, nausea, diarrhea, reactive hepatitis, hemolytic anemia and spinal hypoplasia, gastrointestinal intolerance, headache, transient skin allergies, metallic taste and lactic acidosis.

Contraindications and Precautions

Metformin. Contraindications: Hypersensitivity to the drug, type 1 diabetes mellitus. diabetic ketoacidosis, kidney failure, liver failure, heart or lung failure, severe malnutrition, chronic alcoholism and acute alcohol poisoning. Pregnancy and lactation

Interactions

Metformin. Decreases the absorption of vitamin B12 and folic acid. Sulfonylureas promote the hypoglycemic effect. Cimetidine increases the plasma concentration of metformin. Linagliptin should not be used in patients with type 1 diabetes, nor for the treatment of diabetic ketoacidosis.

METHYLPREDNISOLONE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Shock.	Intramuscular or slow intravenous.
	Each vial with lyophilisate contains	Severe inflammation.	Adults:
	Methylprednisolone sodium succinate equivalent to 500 mg methylprednisolone.	Bronchial asthma crisis.	10 to 250 mg every 4 hours. Initial: 30 mg/kg. Maintenance: According to each particular case.
010.000.0476.00	Package with 50 vials and 50 ampoules with 8 mL of diluent.		Children:
			From 1 to 2 mg/kg/day, divide or fraction into four doses.
	INJECTABLE SUSPENSION	Inflammatory arthropathies.	Intramuscular, intra-articular, intralesional.
	Each mL contains: Acetate	Severe inflammation.	Adults:
	Methylprednisolone 40 mg.		Intramuscular: 10 to 80 mg/day. Intra-articular: 40 to 80 mg every 1 to 5
010.000.3433.00	A vial with 2 mL.		weeks. Intralesional: 20 to 60 mg.

Generalities

Glucocorticoid that inhibits phospholipase A2, therefore inhibiting the synthesis of prostaglandins, thromboxanes and leukotrienes.

Risk in Pregnancy

С

Adverse effects

Posterior subcapsular cataract, adrenal hypoplasia, Cushing's syndrome, obesity, osteoporosis, gastritis, superinfections, glaucoma, hyperosmolar coma, hyperglycemia, muscle catabolism, delayed healing, growth retardation and hydroelectrolyte disorders.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, active tuberculosis, diabetes mellitus, systemic infection, peptic ulcer, hypertensive crisis, liver and kidney failure and immunosuppression.

Interactions

Thiazide diuretics, furosemide and amphotericin B increase hypokalemia. Rifampicin, phenytoin and phenobarbital increase its hepatic biotransformation. Estrogens decrease its biotransformation. Antacids decrease its absorption. With digitalis the risk of digitalis poisoning increases. Increases the biotransformation of isoniazid.

OCTREOTIDE

Clu	e	Description	Indications	Route of administration and dosage
		INJECTABLE SUSPENSION	Acromegaly.	Deep intramuscular.
		Each vial contains: Octreotide acetate equivalent to	Functional gastro- pancreatic endocrine	Adults:
		20 mg of octreotide.	tumors.	10-30 mg every 4 weeks.
010.000.5	5171.00	Container with a vial and two vials with diluent.		

010.000.5171.01	Package with a vial and a syringe prefilled with 2.5 mL of diluent.		
010.000.5171.02	Container with a vial and a syringe prefilled with 2 mL of diluent.		
	· · · · · · · · · · · · · · · · · · ·	Generalities	1
Synthetic analogu	e of somatostatin that acts as a potent in		」 ecially growth hormone, insulin and glucagon.
Risk in Pregr	nancy x		_
	A	Adverse effects	
			diarrhea, steatorrhea, hypoglycemia or hyperglycemia batitis without cholestasis during the first hours or
	Controindi	actions and Dressutions	1
	: Hypersensitivity to the drug. epatitis and diabetes mellitus.	cations and Precautions	1
Treedutions. In the			-
		Interactions	
•	he plasma concentration of cyclosporine omocriptine increases the availability of b		n. Concomitant administration of
PARICALCI			
	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Prevention and treatment	Intravenous.
	Each vial or vial contains:	of hyperparathyroidism secondary to chronic renal failure resistant to calcitriol.	From 0.04 µg/kg to 0.1 µg/kg of body weight, every third day.
	Paricalcitol 5µg		
010.000.1100.00	Container with 5 vials or vials with 1mL.		
	CAPSULE		Oral.
	Each capsule contains: Paricalcitol 2 µg.		Adults and people over 18 years of age:
010.000.1101.00	Container with 30 capsules.		Initial dose.
	CAPSULE	1	Based on basal levels of
	Each capsule contains:		Intact Parathyroid Hormone (HPTi).
	Paricalcitol 4 µg.		PHT < 500 pg/mL; 2 μ g three times a week.
010.000.1102.00	Container with 30 capsules.		HPTi ÿ 500 pg/mL; 4 μg three times a day week.
		Generalities	1
Synthetic analog	ue of calcitriol, metabolically active form o		J icalcitol have been shown to reduce
	one levels and normalize calcium and ph		
parathyroid horm			
parathyroid horm	Risk in Pregnancy	c	
parathyroid hormo	Risk in Pregnancy	c dverse effects	1
	Risk in Pregnancy	Adverse effects] niting, edema, lightheadedness,
Chills, fever, cold	Risk in Pregnancy	Adverse effects ntestinal bleeding, nausea, vor] niting, edema, lightheadedness,
Chills, fever, cold pneumonia. Contraindications	Risk in Pregnancy	Adverse effects ntestinal bleeding, nausea, vor cations and Precautions] niting, edema, lightheadedness,

Caution should be used when dosing paricalcitol with ketoconazole and other P450 3rd inhibitors.

Clue	Description	Indications	Route of administration and dosage
	TABLET	Diabetes mellitus type 2.	Oral.
	Each tablet contains:		Adults:
	Pioglitazone hydrochloride		
	equivalent to 15 mg of pioglitazone.		15 to 30 mg every 24 hours.
010.000.4149.00	Package with 7 tablets.		
		Generalities	7
hiazolidinedior	e that improves insulin sensitivity		
			of genes that control lipids and glucose
Risk in Prec	nancy x		
		Adverse effecte	-
Pespiratory trac	t infection headache sinusitis m	Adverse effects	
Respiratory trac		iyalgia, dental disorders, priaryn	
	Contr	aindications and Precautions	
	s: Hypersensitivity to the drug, pr		heart failure.
Precautions: Pre	emenopausal women may increas	se the risk of pregnancy.	
		Interactions	
Induite the state of a set of			
innibits the actio	on of contraceptives. Ketoconazol	e inhibits its metabolism.	
innibits the actio	on of contraceptives. Ketoconazolo	e inhibits its metabolism.	
Innibits the action	n of contraceptives. Ketoconazoli	e inhibits its metabolism.	
		e inhibits its metabolism.	
		e inhibits its metabolism.	Route of administration and dosage
RAVASTA	ŢIN		Route of administration and dosage
PRAVASTA	TIN Description	Indications	,
PRAVASTA	TIN Description	Indications	Oral. Adults:
PRAVASTA	TIN Description TABLET Each tablet contains:	Indications	Oral.
PRAVASTA ^{Clue}	TIN Description TABLET Each tablet contains: Pravastatin sodium 10 mg.	Indications	Oral. Adults:
PRAVASTA Clue	TIN Description TABLET Each tablet contains: Pravastatin sodium 10 mg.	Indications Hypercholesterolemia. Generalities	Oral. Adults:
PRAVASTA Clue	T/N Description TABLET Each tablet contains: Pravastatin sodium 10 mg. Package with 30 tablets. c cholesterol synthesis and increa	Indications Hypercholesterolemia. Generalities	Oral. Adults:
PRAVASTA Clue	T/N Description TABLET Each tablet contains: Pravastatin sodium 10 mg. Package with 30 tablets. c cholesterol synthesis and increa	Indications Hypercholesterolemia. Generalities uses LDL catabolism. x	Oral. Adults:
PRAVASTA Clue	T/N Description TABLET Each tablet contains: Pravastatin sodium 10 mg. Package with 30 tablets. c cholesterol synthesis and increa	Indications Hypercholesterolemia. Generalities uses LDL catabolism. X Adverse effects	Oral. Adults: 10 to 40 mg every 24 hours, preferably at night.
PRAVASTA Clue	T/N TABLET Each tablet contains: Pravastatin sodium 10 mg. Package with 30 tablets. c cholesterol synthesis and increas	Indications Hypercholesterolemia. Generalities uses LDL catabolism. X Adverse effects	Oral. Adults: 10 to 40 mg every 24 hours, preferably at night.
PRAVASTA Clue	T/N TABLET Each tablet contains: Pravastatin sodium 10 mg. Package with 30 tablets. c cholesterol synthesis and increation increatio	Indications Hypercholesterolemia. Generalities uses LDL catabolism. X Adverse effects	Oral. Adults: 10 to 40 mg every 24 hours, preferably at night.

Interactions

Cyclosporine increases plasma levels of pravastatin.

Г

PREDNISOLONE

PREDNISOL	.ONE		
Clue	Description	Indications	Route of administration and dosage
	ORAL SOLUTION	Inflammatory and	Oral.
	Each 100 mL contains:	autoimmune diseases.	Adults and children:
	Prednisolone sodium phosphate equivalent to 100 mg of prednisolone.	Bronchial asthma.	Initial dose: 1-2 mg/kg body weight/day.
	predhisolone.	Diseases	Maintenance dose: 0.1-0.5 mg/kg

				-
010.000.2482.00 Contai	ner with 100 mL bottle and glass		neoplastic.	body weight/day.
	20 mL graduated.			
				~
	,		Generalities	
Anti-inflammatory and	I glucocorticoid action greater t	han hydrocortiso	ne, with a significant decrease in n	nineralocorticoid action.
Risk in Preg	nancy	С		
rtioit in r rogi	inditoy			
		A	dverse effects	
				nsion, increased susceptibility to infections,
peptic ulcer, myo	pathy, behavioral disord	ers, posterior	subcapsular cataract, osteo	oporosis, obesity and adrenal suppression.
		Contraindi	cations and Precautions	Г
Contraindications	ı s: Hypersensitivity to the		isone and systemic infection	U DIOCESSES.
	,,, io alo			
			Interactions	
•	turates and phenytoin sh	norten the elin	nination half-life. Oral contra	aceptives can prolong their half-
life.				
ROSIGLITA	1			
ROSIGLITAZ ^{Clue}	Description		Indications	Route of administration and dosage
	1	1	Indications Diabetes mellitus type 2.	Route of administration and dosage Oral.
	Description	1		-
	Description TABLET			Oral.
	Description TABLET Each tablet contains:			Oral. Adults: 4 mg every 24 hours, you can
Clue	Description TABLET Each tablet contains: Rosiglitazone maleate equivalen rosiglitazone			Oral. Adults:
	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler			Oral. Adults: 4 mg every 24 hours, you can
Clue 010.000.4150.00	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets.			Oral. Adults: 4 mg every 24 hours, you can
Clue 010.000.4150.00	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets.	nt to 4 mg	Diabetes mellitus type 2.	Oral. Adults: 4 mg every 24 hours, you can
Clue 010.000.4150.00 010.000.4150.01	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 28 tablets.	nt to 4 mg	Diabetes mellitus type 2. Generalities	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 28 tablets.	nt to 4 mg	Diabetes mellitus type 2. Generalities r receptor gamma that inter	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 28 tablets.	nt to 4 mg	Diabetes mellitus type 2. Generalities	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 28 tablets.	nt to 4 mg ation activato Reduces insu	Diabetes mellitus type 2. Generalities r receptor gamma that inter	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 14 tablets. Package with 28 tablets.	nt to 4 mg	Diabetes mellitus type 2. Generalities r receptor gamma that inter	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response	Description TABLET Each tablet contains: Rosiglitazone maleate equivaler rosiglitazone Package with 14 tablets. Package with 14 tablets. Package with 28 tablets.	nt to 4 mg ration activato Reduces insu d	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. f the peroxisomal prolifer on glucose metabolism.	nt to 4 mg ation activato Reduces insu d	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. f the peroxisomal prolifer on glucose metabolism.	nt to 4 mg ation activato Reduces insu d	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. f the peroxisomal prolifer on glucose metabolism.	nt to 4 mg ation activato Reduces insu d n of LDL chole	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves dverse effects esterol, headache, back pai	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. if the peroxisomal prolifer on glucose metabolism. nancy y tract infection, elevation	nt to 4 mg ration activato Reduces insu d n of LDL chole Contraindi	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. i the peroxisomal prolifer on glucose metabolism. nancy / tract infection, elevation s: Hypersensitivity to the	nt to 4 mg ration activato Reduces insu d n of LDL chole Contraindi	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves dverse effects esterol, headache, back pai	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg Upper respiratory Contraindications	Description TABLET Each tablet contains: Rosiglitazone maleate equivalet rosiglitazone Package with 14 tablets. Package with 28 tablets. i the peroxisomal prolifer on glucose metabolism. nancy / tract infection, elevation s: Hypersensitivity to the	nt to 4 mg ration activato Reduces insu d n of LDL chole Contraindi	Diabetes mellitus type 2. Generalities r receptor gamma that inter lin resistance and improves dverse effects esterol, headache, back pai cations and Precautions	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg Upper respiratory Contraindications Precautions: Hea	Description TABLET Each tablet contains: Rosiglitazone maleate equivaled rosiglitazone Package with 14 tablets. Package with 28 tablets. if the peroxisomal prolifer on glucose metabolism. nancy y tract infection, elevation s: Hypersensitivity to the art failure.	nt to 4 mg ration activato Reduces insu d n of LDL chole Contraindi	Diabetes mellitus type 2. Generalities r receptor gamma that inter Ilin resistance and improves dverse effects esterol, headache, back pai	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.
Clue 010.000.4150.00 010.000.4150.01 It is an agonist of insulin response Risk in Preg Upper respiratory Contraindications	Description TABLET Each tablet contains: Rosiglitazone maleate equivaled rosiglitazone Package with 14 tablets. Package with 28 tablets. if the peroxisomal prolifer on glucose metabolism. nancy y tract infection, elevation s: Hypersensitivity to the art failure.	nt to 4 mg ration activato Reduces insu d n of LDL chole Contraindi	Diabetes mellitus type 2. Generalities r receptor gamma that inter lin resistance and improves dverse effects esterol, headache, back pai cations and Precautions	Oral. Adults: 4 mg every 24 hours, you can increase the dose to one tablet every 12 hours. acts in the cell nucleus, activating the s glucose uptake.

ROSUVASTATIN

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hypercholesterolemia.	Oral.
	Each tablet contains: Rosuvastatin calcium equivalent to	Hyperlipidemia.	Adults:
	10 mg rosuvastatin		10 or 20 mg every 24 hours, at night.
010.000.4023.00	Package with 30 tablets.		
	Each tablet contains:		

	Rosuvastatin calcium equival 20 mg rosuvastatin	ent to		
010.000.6277.00	Package with 30 tablets.			
		Ge	eneralities	
				rol synthesis and LDL-C clearance.
	90% bound to plasma		oumin. The parent compour	nd accounts for more than 90% of the
		bry dolivity.		
Risk in Preg	gnancy	С		
		Adv	erse effects	
Headache, mya	lgia, asthenia, constipa	tion, dizziness, na	usea, abdominal pain, pruri	tus, rash and urticaria.
		Contraindicat	ions and Precautions	
Contraindication	ns: Hypersensitivity to t			
			s of alcohol, or have a histo	bry of liver disease.
		In	teractions	
				them. Rosuvastatin increases plasma
	rations. Concomitant us (0-t) of rosuvastatin.	se with gemfibrosil	increases the risk of	
SIMVASTA	TIN			
Clue	Descript	on	Indications	Route of administration and dosage
	TABLET		Hypercholesterolemia.	Oral.
	Each tablet contains:			Adults:
	Simvastatin 20 mg.			
010.000.4124.00	Package with 14 tablets.			20-40 mg every 24 hours, preferably at night.
010.000.4124.01	Package with 30 tablets.			
010.000.4124.01	T dokage with oo tablets.			
		Ge	eneralities	
Competitive inh	ibitor of HMG-CoA redu		r effect in reducing LDL.	
•				
Risk in Preg	gnancy	х		
		Adv	erse effects	
Muscle pain, na	usea, vomiting, diarrhe	a, constipation, ab	dominal pain, headache, di	zziness and elevation of liver
transaminases.				
		Contraindicat	ions and Precautions	
Contraindication	ns: Hypersensitivity to the		/, lactation and active liver	disease.
	erapeutic with fibrates			
		In	teractions	
Cimetidine, rani	tidine and omeprazole		vailability. Rifampin decrea	ses it.
S <u>ITAGLIP</u>	<u>TIN</u>		-	
Clue	COMPRESSED	ription	Indications	Route of administration and dosage
			Diabetes mellitus type 2.	
	Each tablet contains:	anahudata aminintari		Adults:
	Sitagliptin phosphate m to 100 mg of sitagliptin.			50 mg every 12 hours or 100 mg every 2 hours as
010.000.4152.00				monotherapy or in combination treatment with
010.000.4152.01	Package with 14 tablets Package with 28 tablets			metformin or glitazones.
			4	
	COMPRESSED		1	

	Each tablet contains: Sitagliptin phosphate monohydrate equivalent to 50 mg sitagliptin
010.000.4153.00	Package with 14 tablets.
010.000.4153.01	Package with 28 tablets.
	TABLET
	Each tablet contains: Hydrochloride
	Sitagliptin Monohydrate equivalent
	to 100 mg of Sitagliptin
010.000.7120.00	Container with 14 tablets
010.000.7120.01	Container with 28 tablets
	TABLET
	Each tablet contains: Hydrochloride
	Sitagliptin Monohydrate equivalent
	to 50 mg of Sitagliptin
010.000.7121.00	Container with 14 tablets
010.000.7121.01	Container with 28 tablets

Generalities

It is a member of a class of antihyperglycemic agents called dipeptidylpeptidase 4 (DPP-4) inhibitors, which improve glycemic control in patients with type 2 diabetes by increasing concentrations of incretin hormones.

Risk in Pregnancy

d Adverse effects

Abdominal pain, nausea, vomiting and diarrhea.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Precautions: Dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with end-stage renal disease requiring hemodialysis.



The area under the curve and maximum plasma concentration (AUC and Cmax) increased slightly by 11% and 18%, respectively, when sitagliptin and digoxin were co-administered. Besides; The AUC and Cmax of sitagliptin increased by approximately 29% and 68%, respectively, when single oral doses of sitagliptin 100 mg and cyclosporine 600 mg were coadministered.

SITAGLIPTIN, METFORMIN

Clue	Description	Indications	Route of administration and dosage
	TABLET or TABLET	Treatment of type 2 diabetes	Oral.
	Each tablet contains: Sitagliptin phosphate monohydrate	mellitus in adult patients with failure in glycemic control with metformin or sitagliptin monotherapy or patients at with	Adults: One tablet or tablet every 12 hours.
	Hydrochloride of sitagliptin Monohydrate	high risk of with hypoglycemia, adult patients who are currently stable on metformin plus sitagliptin treatment.	
	equivalent to 50 mg sitagliptin Metformin hydrochloride 500 mg.	in in	
010.000.5705.00	Package with 28 tablets or tablets.	with	
010.000.5705.01	Package with 56 tablets or tablets.		
	TABLET or TABLET		
	Each tablet contains: Sitagliptin Phosphate Monohydrate		

	~ Hydrochloride of sitagliptin Monohydrate
	equivalent to 50 mg sitagliptin Metformin hydrochloride 850 mg.
010.000.5703.00 010.000.5703.01	Package with 28 tablets or tablets. Package with 56 tablets or tablets.
	TABLET or TABLET Each tablet contains: Sitagliptin Phosphate Monohydrate
010.000.5704.00	 Hydrochloride of sitagliptin Monohydrate
	equivalent to 50 mg sitagliptin Metformin hydrochloride 1000 mg. Package with 56 tablets or tablets.

Generalities

The mechanism of action of the combination of sitagliptin and metformin in the same tablet is characterized by the fact that it acts on the three main defects associated with type 2 diabetes: the deficit in insulin production by beta cells, insulin resistance and excess glucose production by the liver. The sitagliptin component of the tablet increases the concentration of the active forms of incretins, thereby enhancing a natural process in the body that increases the synthesis and release of insulin by pancreatic cells, and decreases the secretion of glucagon by alpha cells. of the pancreas, thereby reducing glucose production by the liver. Metformin, the other component of the tablet, is one of the pillars of diabetes treatment; it acts on insulin resistance, increasing the uptake and use of glucose. Metformin also reduces glucose production by the liver, in a complementary way to sitagliptin.

Risk in Pregnancy

Adverse effects

с

Diarrhea, nausea, dyspepsia, flatulence, vomiting, headache, hypoglycemia.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs. Nephropathy or renal dysfunction, acute myocardial infarction or septicemia, acute or chronic metabolic acidosis.

Precautions: Sitagliptin/metformin should not be used in patients with type 1 DM or to treat diabetic ketoacidosis. Monitor kidney function. Metformin should not be used in patients with moderate to moderate renal impairment. severe due to the risk of lactic acidosis.

Interactions

Pharmacokinetic interaction studies have not been done with Sitagliptin, metformin, but with their individual components, sitagliptin and metformin.

Sitagliptin: In drug interaction studies, sitagliptin had no clinically important effects on

the pharmacokinetics of the following medications: metformin, rosiglitazone, glyburide, simvastatin, warfarin and oral contraceptives. According to these data, sitagliptin does not inhibit the cytochrome P-450 isoenzymes CYP3A4, 2C8 and 2C9.

Furosemide: A study on the interaction of single doses of metformin and furosemin in healthy subjects showed that coadministration affected the pharmacokinetic parameters of both compounds. Furosemide increased the plasma and blood Cmax by 22% and the blood AUC of metformin by 15%, without any significant change in its renal clearance. When co-administered with metformin, the Cmax and AUC of furosemide were 31 and 12% lower, respectively, than when administered alone, and its terminal half-life was decreased by 32%, without any significant change in its renal clearance. There is no information available about the interaction of metformin and furosemide when coadministered for a long time.

Nifedipine: A single-dose interaction study of metformin and nifedipine in healthy subjects demonstrated that coadministration of nifedipine increased the Cmax and AUC of metformin by 20% and the amount of metformin excreted in the urine by 9%. Its Tmax and half-life were unchanged. Nifedipine increases the absorption of

metformin, and this had minimal effects on nifedipine.

Cationic medications: Cationic medications (such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, or vancomycin) that are eliminated by renal tubular secretion can theoretically interact with metformin by competing with it for tubular transport systems. common kidney. Certain medications tend to cause hyperglycemia and may impede blood glucose control. These medications include

thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. When any of these medications are administered to a patient who is taking Sitagliptin, metformin, they should be closely monitored to ensure good blood glucose control.

SOMATROPIN

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Poor growth due to inadequate growth hormone secretion	Intramuscular or subcutaneous.
	Each vial with lyophilisate contains:	endogenous.	Children:
	Biosynthetic somatropin 1.33 mg equivalent to 4 IU.	, , , , , , , , , , , , , , , , , , ,	0.16 IU/kg, three times a week. Do not administer more than 12 IU/m2 of body surface area per week.
010.000.5163.00	Container with vial and vial or vial with 1 or 2 mL of diluent.		
	INJECTABLE SOLUTION		Subcutaneous or intramuscular.
	Each cartridge with two		Adults:
	compartments, one with lyophilisate, contains:		0.018 to 0.036 IU/kg body weight/day.
010.000.5167.00	Somatropin 5.3 mg equivalent to 16 IU and another with the diluent.		Children:
010.000.5167.01	Package with a cartridge with two		2.1 to 3 IU/ m2 of body surface/day or
010.000.5167.01	compartments, one with lyophilisate and the other with the diluent.		0.7 to 1.0 mg/ m2 of body surface area / day.
	Container with vial with lyophilisate and vial with 2 mL of diluent.		
	INJECTABLE SOLUTION	Poor growth due to inadequate secretion of endogenous growth	Subcutaneous (using hidden needle autoinjector).
	Each vial with lyophilisate contains:	hormone.	Children:
	Biosynthetic somatropin 8 mg		0.18 to 0.25 mg/kg body weight (0.54 to
	equivalent to 24 IU.	Growth hormone deficiency in adults.	0.80 IU/kg body weight) per week. It is recommended to divide into three to six
010.000.5174.01	Package with a vial with lyophilisate and		applications.
	multidose autoinjector.		Adults:
010.000.5174.02	Package with a viel with lyaphilizate and a		0.08 mg/kg body weight (0.125 IU/kg)
010.000.0114.02	Package with a vial with lyophilisate and a cartridge (prefilled syringe) with diluent.		per week, which can be increased to 0.16 mg/kg (0.25 IU/kg body weight).
			In both cases it is recommended to divide it into six or
	INJECTABLE SOLUTION	Treatment of children with growth	seven applications per week. Subcutaneous or intramuscular.
		hormone deficiency.	
	Each cartridge with two		Children:
	compartments, one with lyophilisate, contains:		2.1 to 3.0 IU/m2 body surface area/day.
	Somatropin 13.80 mg equivalent to 36 IU and another with the 1 mL diluent.		0.7 to 1.0 mg/m2 body surface area/day
010.000.5694.01	Package with a cartridge prefilled with 1.5		
	mL to be administered in an autoinjector		
	device.		
	INJECTABLE SOLUTION	Growth hormone secretion deficiency.	Subcutaneous. Children:
	Each milliliter contains:		25 to 35 ÿg /Kg of body weight/day or 0.7 to
	Somatropin 3.30 mg.		1.0 mg/m2 body surface area/day.
010.000.5750.00	Package with a 1.5 mL (5 mg/1.5 mL) pre-filled		
	pen.		

	Each milliliter contains:		
	Somatropin 6.70 mg		
010.000.5751.00	Package with a 1.5 mL (10 mg/1.5 mL) pre-filled		
	pen.		
	INJECTABLE SOLUTION		
	Each milliliter contains:		
	Somatropin 10.0 mg.		
010.000.5752.00	Package with a 1.5 mL pre-filled pen (15 mg/1.5		
	mL).		
	INJECTABLE SOLUTION		
	Each milliliter contains:		
	Recombinant somatropin 6,666 mg.		
010.000.5754.00	Container with cartridge with 1.5 mL.		
	[(10 mg/1.5 mL) equivalent to 30 IU]		
	for multidose injector device.		
		Generalities	7

Growth hormone, with anabolic action.

Risk in Pregnancy

Adverse effects

С

Hypersensitivity, hypothyroidism, hyperglycemia, benign intracranial hypertension, otitis media. Very common: In adults peripheral edema. Common: In adults, headache, paresthesia, arthralgia, myalgia, and joint stiffness. Uncommon: In adults type 2 diabetes mellitus, carpal tunnel syndrome, pruritus, muscle stiffness and pain at the injection site. In children Headache, injection site pain and injection site reaction NOS. Rare: In children NOS rash, arthralgia, myalgia and peripheral edema.

Contraindications and Precautions

Contraindications: Patients who present evidence of tumor activity, neoplasms must be inactivated and antitumor therapy must be completed before instituting treatment, pregnancy and lactation, promotion of longitudinal growth in children with closed epiphysis, patients with acute critical illness, patients suffering complications after open heart surgery, patients after abdominal surgery, multiple trauma respiratory complications or similar conditions. Hypersensitivity to some of the components of the formula, patients with Prader-Willi Syndrome who have severe obesity or respiratory deficiency. Diabetes with active proliferative retinopathy or severe non-proliferative retinopathy. Precautions: Do not exceed the maximum recommended daily dose; stimulation of longitudinal growth in children can be expected until the epiphyseal discs are closed.

Chronic renal failure: During treatment, uremia should be conservatively managed with regular medication, and dialysis should be maintained if necessary. Renal function should be monitored to detect an excessive decrease or increase in the glomerular filtration rate (which could imply hyperfiltration). Neoplasms: Somatropin treatment should be discontinued in case of any development or recurrence of cancer. There is no evidence of an increased risk of new primary cancers in children or adults treated with somatropin. In patients in complete remission of tumors or cancer, somatropin therapy has not been associated with an increase in the relapse rate. Benign intracranial hypertension: Very rare cases have been reported; if so, treatment should be suspended. Thyroid function: Hypothyroidism interferes with the response to somatropin treatment, patients should undergo regular testing regarding their thyroid function and should receive thyroid hormone replacement therapy when indicated.

Interactions

Concomitant treatment with glucocorticoids inhibits growth-promoting effects. In adults with growth hormone deficiency, it suggests that the administration of somatropin may increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, such as sex steroids, corticosteroids, anticonvulsants, and cyclosporines. In patients treated with insulin, an adjustment of the insulin dose may be necessary after initiating treatment with somatropin.

Clue	•	Description	Indications	Route of administration and dosage
		INJECTABLE SOLUTION Each vial with lyophilisate contains: Taliglucerase alfa 200 U.	Enzyme replacement therapy for the treatment of Gaucher disease type 1 for adults and pediatric patients.	Intravenous. Adults and pediatric patients: 30 to 60 U/Kg of body weight, once every two weeks.
010.000.5614	4.00	Container with vial bottle with lyophilized powder.		

TALIGLUCERASE ALFA

	ſ	1	Generalities	1
	ment therapy is the stand nsate for ÿ-GCD deficient	dard treatment	t for GD and is based on the	e premise of administering recombinant
Risk in Pregn	ancy	b		
	г	Δ	dverse effects	1
	L on adverse reactions are rythema and flushing.			J ıritus, nausea, peripheral edema, _
	s: Hypersensitivity to the sponse to antibodies.		cations and Precautions ots, and children under 18 ye] ears of age.
]		Interactions	1
No pharmacodynami	ic interaction studies with other	drugs were perfo	ormed.	-
TERIPARAT	rine			
	DE Description	I	Indications	Route of administration and dosage
010.000.4174.00	INJECTABLE SOLUTION Each milliliter contains: Teriparatide 250 µg. Pen container with assembled 2.4	4 mL cartridge.	Women and men with osteoporosis with previous hip or spine fractures, high risk of new fractures and who have not responded to treatment with calcitriol or bisphosphonates.	Subcutaneous. Adults: 20 µg every 24 hours.
	Г		Generalities	1
•	that has an identical sequence calcium and phosphate metaboli			e 84-amino acid natural human parathyroid hormone.
Risk in Preg	nancy	С		
	[A	dverse effects]
Nausea, arthralg	ia, leg cramps, dizziness	, depression,	insomnia, vertigo.	
	s: Hypersensitivity to the tory of radiotherapy.		cations and Precautions]
	[Interactions]
	mportance. Concomitant did not modify the advers		n with Raloxifene did not alt	er the expected response with
TESTOSTE	RONE			
Clue	Description		Indications	Route of administration and dosage
	INJECTABLE SOLUTION		Hypogonadism	Intramuscular.

	INJECTABLE SOLUTION	Hypogonadism male.	Intramuscular.
	Each vial contains:		Adults:
	Testosterone enanthate 250 mg.	Breast cancer.	Hypogonadism: 50 to 400 mg every 2 to 4 weeks.
010.000.1061.00	Vial container with 1 mL.		Delayed puberty: 25 to 200 mg every 2 to 4 weeks for 6 months.
	CAPSULE	Hypogonadism male.	Oral.
	Each capsule contains:		Adults:
	Testosterone undecanoate 40 mg.		Start: 120 to 160 mg/day for 3 weeks. Maintenance: 40 to 120 mg/day. Adjust the
010.000.5164.00	Container with 30 capsules.		dose according to the patient's response.
010.000.5164.01	Container with 60 capsules.		
		Generalities	

Androgen that promotes the growth and development of sexual organs and secondary male characteristics.

		Y		
Risk in Pregn	ancy	х		
			Adverse effects	
Fluid retention, he leukopenia.	patotoxicity, acne, hair			ing, urticaria, anaphylactic reactions and
·				
			ications and Precautions	
Contraindications: Hy	persensitivity to the drug, p	rostate cancer, brea	ast cancer in men, pregnancy ar	nd lactation.
		8	Interactions	
None of clinical im	portance.			
THIAMAZOL				
Clue	Descript	ion	Indications	Route of administration and dosage
	TABLET		Hyperthyroidism.	Oral.
	Each tablet contains:			
	Thiamazol 5 mg.			Adults and children: Initial dose of 5 to 20 mg/ every 8 hours.
	-			If hypothyroidism occurs, the dose can be reduced until
010.000.1022.00	Package with 20 tablets.			euthyroidism is achieved (usually reduced to one-third
				of the initial dose).
			Generalities	
Inhibits the synthesis	of thyroid hormone.			
, ,	· · , · · · · · ·			
Risk in Pregn	ancy	d		
9a-	- 14			
		3.	Adverse effects	
Lymphadenopathy	v, leukopenia, agranuloo	cytosis, aplastic a	anemia, diarrhea, vomiting,	jaundice, headache and vertigo.
		Contraindi	cations and Precautions	
Contraindications:	Hypersensitivity to the		dism and breastfeeding.	
Precautions: Pregna		0, 11	0	
			Interactions	
None of clinical im	portance.	· •		

THYROXINE - TRIYODOTYRONINE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Hypothyroidism.	Oral.
	Each tablet contains:		Adults:
	Thyroxine 100 μg.		Start: 50 μg of thyroxine and 10 μg of triiodothyronine
	Triiodothyronine 20 µg.		per day. Subsequently increase the dose (half a tablet) every two weeks until the therapeutic effect is obtained.
010.000.1005.00	Package with 50 tablets.		every two weeks until the therapeutic enect is obtained.

Generalities

Thyroid hormones stimulate brain and body development, heat production and promote the utilization of proteins, carbohydrates, lipids, vitamins, electrolytes and water.

Dials in	Descension	
RISK IN	Pregnancy	

то

Adverse effects

Tachycardia, angina pectoris, nervousness, insomnia, headache, weight loss, diarrhea, cramps.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, recent myocardial infarction, thyrotoxicosis.

Increases insuli	n and oral hypoglycemic requirements.	Interactions Reduces the effects of or	al anticoagulants.
VASOPRE	SSIN		
Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Diabetes insipidus	Intramuscular or subcutaneous.
	Each vial contains:	nephrogenic and non- psychogenic.	Adults:
	Vasopressin 20 IU.	psychogenic.	5 to 10 IU every 8 to 12 hours.
			Maximum 60 IU/day.
			Children:
010.000.4154.00	Container with a vial.		2.5 to 10 IU every 8 to 12 hours.
	[Generalities	
It increases the	permeability of the convoluted tubules	and promotes water reabs	orption, producing an increase in urine osmolar
and a decrease	in urine volume.		
Risk in Preg	gnancy b		
		Adverse effects	
Angioneurotic e	dema, diarrhea, vomiting, angina pecto	ris, systemic arterial hyper	rtension and arrhythmias.
C C			
		dications and Precautions	
	 s: Hypersensitivity to the drug. ronic nephritis, epilepsy, bronchial asth 	ma boart failura coronar	v boart discoss and liver discoss
Frecautions. Ch	Torne neprintis, epilepsy, broneniai astr	ina, nearrianure, coronar	y heart disease and liver disease.
		Interactions	
.	, chlorpropamide and clofibrate may in		

and alcohol decrease its antidiuretic effect.

VELAGLUCERase ALFA

Clue	Description	Indications	Route of administration and dosage
010.000.5615.00	Description INJECTABLE SOLUTION Each vial with lyophilisate contains: Velaglucerase alfa 400 U. Container with vial bottle with freeze-dried.	Indications replacement therapy enzymatic for the treatment of Gaucher disease type 1.	Route of administration and dosage Intravenous. Children, adolescents and adults. 60 U/Kg of body weight, every two weeks. Adjust the dose according to the patient's response to enzyme replacement therapy. Reconstitute with 4.3 mL of sterile distilled water. Once reconstituted, the solution contains: 100 U/mL of Velaglucerase alfa in an extraction volum of 4.0 mL. Dilute in 100 mL of 0.9% physiological sodium chlorid
			Dilute in 100 mL of 0.9% physiological sodium chlorid solution. Administer the solution for 60 minutes.

Specific glucocerebroside hydrolytic lysosome enzyme obtained by gene activation technology in a human cell line. Glycoprotein that catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide in the lysosome, thereby reducing the amount of accumulated glucocerebroside and increasing Hb concentration and platelet count, and reducing liver and spleen volumes.

Risk in Pregnancy

b

Adverse effects

Headache, dizziness, bone and back pain, arthralgia, perfus-related reaction, asthenia/fatigue, pyrexia/increased body temperature, hypersensitivity, tachycardia, hyper and hypotension, flushing, abdominal pain/pain in upper abdomen, nausea, rash, urticaria, prolongation of activated partial thromboplastin time.

Contraindications and Precautions

Interactions

Contraindications: Hypersensitivity to the drug. Precautions: Allergic hypersensitivity reactions.

No formal interaction studies have been performed.

VILDAGLIPTIN, METFORMIN

Clue	Description	Indications	Route of administration and dosage
	COMPRESSED	Diabetes Treatment	Oral.
	Each tablet contains: Vildagliptin 50 mg. Metformin hydrochloride 500 mg.	Mellitus Type 2 in patients in whom there is weight gain that causes problems, when thiazolidinediones	Adults: One tablet every 12 hours.
010.000.5700.00	Package with 30 tablets.	are contraindicated, or if the patient had a poor response	
	COMPRESSED	or intolerance to them in the past, or in patients who	
	Each tablet contains: Vildagliptin 50 mg. Metformin hydrochloride 850 mg.	are currently stable on treatment with	
010.000.5701.00	Package with 30 tablets.	metformin + vildagliptin	
	COMPRESSED	-	
	Each tablet contains: Vildagliptin 50 mg. Metformin hydrochloride 1000 mg.		
010.000.5702.00	Package with 30 tablets.		

Generalities

Vildagliptin acts by inhibiting the action of the enzyme dipeptidyl-peptidase 4 (DPP-4), which increases the levels of incretin hormones -GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide)stimulating insulin secretion and regulating glucagon secretion, depending on glucose concentrations. For its part, Metformin inhibits gluconeogenesis and glycogenolysis, reduces hepatic glucose production, increases insulin sensitivity, improves peripheral glucose uptake and utilization, and delays intestinal glucose absorption.

Risk in Pregnancy

С

Adverse effects

Angioedema, liver dysfunction, dizziness, headaches, constipation and peripheral edema, nausea, vomiting, diarrhea, abdominal pain, loss of appetite, decreased absorption of vitamin B12, lactic acidosis, hepatitis, skin reactions such as erythema, pruritus and urticaria, shaking.



Contraindications: Hypersensitivity to drugs.

Precautions: Renal failure or nephropathy, congestive heart failure, acute or chronic metabolic acidosis, such as diabetic ketoacidosis with or without coma; Treatment should be temporarily discontinued in patients undergoing radiological studies in which iodinated contrast media are administered intramuscularly.

Interactions	

Interactions with Vildagliptin: reduced drug interaction capacity; no clinically significant interaction with other oral antidiabetic agents (glibenclamide, pioglitazone, metformin), amLodipine, digoxin, ramipril, simvastatin, valsartan or warfarin, when these drugs are co-administered with vildagliptin. Interactions with metformrine hydrochloride: furosemide, nifedipine, cationic substances; substances that tend to produce hyperglycemia, alcohol.

Machine Translated by Google